Method for producing cultured meat

By expressing and secreting bovine alkaline fibroblast growth factors in rod-shaped bacteria, the problem of high cost of bbFGF in cultured meat production is solved, and efficient animal cell proliferation and reduced production costs are achieved.

CN119053709APending Publication Date: 2024-11-29AJINOMOTO CO INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380034244.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-15
Filing Date
2023-04-14
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

In the production of cultured meat, the manufacturing cost is high, especially the bovine alkaline fibroblast growth factor (bbFGF) is expensive in the high purity purification process.

Method used

Using coryliform bacteria such as Corynebacterium glutamicum as hosts, express and secrete bovine alkaline fibroblast growth factor (bbFGF) through gene construction, avoiding the traditional chromatography purification step, and bbFGF is directly secreted and recovered in the culture medium.

Benefits of technology

It reduces the production cost of bbFGF, improves the proliferation efficiency of animal cells, and achieves efficient cultivation of meat.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

Provided is a method for producing cultured meat. The present invention relates to a bovine basic fibroblast growth factor, which is produced by using a coryneform bacterium as an expression host, and a method for producing a bovine basic fibroblast growth factor. The cultured meat is produced by culturing animal cells in the presence of bbFGF).
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a method for producing cultured meat. Background Art

[0002] In recent years, the technology of producing cultured meat has attracted attention. One problem in the production of cultured meat is that the production cost is high.

[0003] Growth factors such as bovine basic fibroblast growth factor (bbFGF) are typically purified to a high purity by chromatography or the like and used for cell culture in regenerative medicine or the like. Summary of the invention

[0004] Technical problem solved by the invention

[0005] The present invention aims to provide a method for producing cultured meat.

[0006] Technical means of solving problems

[0007] The present inventors have conducted intensive studies to solve the above problems and have found that bovine basic fibroblast growth factor (bbFGF) expressed using coryneform bacteria as a host is effective for the production of cultured meat, thereby completing the present invention.

[0008] That is, the present invention is as follows.

[0009] [1] A method for producing bovine basic fibroblast growth factor (bbFGF) for use in the production of cultured meat, comprising:

[0010] A step of culturing coryneform bacteria having a gene construct for secretory expression of bbFGF to obtain a culture containing bbFGF.

[0011] [2] According to the method, it further comprises:

[0012] A step of removing the bacterial cells of the coryneform bacteria from the culture.

[0013] [3] According to the method, it does not include:

[0014] Procedure for purifying bbFGF.

[0015] [4] According to the method, it does not include:

[0016] A step of purifying bbFGF by chromatography.

[0017] [5] According to the method, wherein

[0018] The gene construct comprises, from 5' to 3' direction, a promoter sequence that functions in coryneform bacteria, a nucleic acid sequence encoding a signal peptide that functions in coryneform bacteria, and a nucleic acid sequence encoding bbFGF,

[0019] bbFGF was expressed as a fusion protein with the signal peptide.

[0020] [6] According to the method, wherein

[0021] The coryneform bacteria are bacteria of the genus Corynebacterium.

[0022] [7] According to the method, wherein

[0023] The coryneform bacteria is Corynebacterium glutamicum.

[0024] [8] A method for producing cultured meat, comprising:

[0025] The process of culturing animal cells in the presence of bovine basic fibroblast growth factor (bbFGF),

[0026] In the method for producing cultured meat, bbFGF is produced by the method. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] [ Figure 1 ] is a photograph showing the results of SDS-PAGE analysis of bbFGF secreted and expressed using Corynebacterium glutamicum (C. glutamicum) as a host.

[0028] [ Figure 2 ] is a diagram showing a chromatogram when bbFGF secreted and expressed using Corynebacterium glutamicum as a host was separated by cation exchange chromatography.

[0029] [ Figure 3 ] is a diagram showing a chromatogram when bbFGF secreted and expressed using Corynebacterium glutamicum as a host was separated by cation exchange chromatography.

[0030] [ Figure 4 ] is a graph showing the growth of bovine muscle stem cells in a serum-free medium supplemented with bbFGF secreted and expressed by Corynebacterium glutamicum as a host. The data (vertical axis) are expressed as relative values ​​with the number of cells at the start of culture being taken as 1.

[0031] [ Figure 5] is a graph showing the proliferation rate (Proliferation Rate) of bovine muscle stem cells in a serum-free medium supplemented with bbFGF secreted and expressed by Corynebacterium glutamicum as a host. The horizontal axis represents the group number.

[0032] [ Figure 6 ] is a graph showing the doubling time of bovine muscle stem cells in a serum-free medium supplemented with bbFGF secreted and expressed by Corynebacterium glutamicum as a host. The horizontal axis represents the group number.

[0033] [ Figure 7 ] is a graph showing the growth of bovine muscle stem cells in a serum-free medium supplemented with bbFGF secreted and expressed by Corynebacterium glutamicum as a host. The data (vertical axis) are expressed as relative values ​​with the number of cells at the start of culture being taken as 1.

[0034] [ Figure 8 ] is a graph showing the proliferation rate (Proliferation Rate) of bovine muscle stem cells in a serum-free medium supplemented with bbFGF secreted and expressed by Corynebacterium glutamicum as a host. The horizontal axis represents the group number.

[0035] [ Fig. 9 ] is a graph showing the doubling time of bovine muscle stem cells in a serum-free medium supplemented with bbFGF secreted and expressed by Corynebacterium glutamicum as a host. The horizontal axis represents the group number. DETAILED DESCRIPTION

[0036] Hereinafter, the present invention is described in detail.

[0037] (1) Active ingredients

[0038] In the present invention, bovine basic fibroblast growth factor (bbFGF) produced using coryneform bacteria as an expression host is used as an active ingredient. bbFGF produced using coryneform bacteria as an expression host is also referred to as an "active ingredient."

[0039] By utilizing the active ingredient, specifically, by culturing animal cells in the presence of the active ingredient, the proliferation of the animal cells can be promoted, that is, the effect of promoting the proliferation of the animal cells is obtained. This effect is also called a "proliferation promoting effect". As for the proliferation promoting effect, for example, it can be confirmed by culturing animal cells in the presence and absence of the active ingredient, and comparing the degree of proliferation of the animal cells. By promoting the proliferation of animal cells, for example, cultured meat can be efficiently produced. That is, the active ingredient can be used to promote the proliferation of animal cells, specifically, it can be used to produce cultured meat.

[0040] Hereinafter, a method for producing an active ingredient using coryneform bacteria as an expression host will be described.

[0041] The active ingredient can be produced by culturing a coryneform bacterium having a gene construct for secretory expression of bbFGF. That is, the method for producing the active ingredient can be a method comprising the step of culturing a coryneform bacterium having a gene construct for secretory expression of bbFGF. This step is also referred to as a "coryneform bacterium culturing step". Through the coryneform bacterium culturing step, bbFGF is secreted and produced, thereby obtaining a culture containing bbFGF (specifically, a culture containing bbFGF produced by secretion). Therefore, the coryneform bacterium culturing step can be specifically a step of culturing coryneform bacteria having a gene construct for secretory expression of bbFGF to secrete and produce bbFGF. In addition, with respect to the coryneform bacterium culturing step, it can be specifically a step of culturing a coryneform bacterium having a gene construct for secretory expression of bbFGF to obtain a culture containing bbFGF.

[0042] The coryneform bacteria (ie, coryneform bacteria used in the production of the active ingredient) are also referred to as “the bacteria of the present invention.” The bacteria of the present invention or the parent strain used to construct the bacteria are also referred to as “hosts.”

[0043] The gene construct (ie, the gene construct for secretory expression of bbFGF) is also referred to as a "bbFGF expression cassette".

[0044] (1-1) Bacteria of the present invention

[0045] The bacterium of the present invention is a coryneform bacterium having a gene construct for secretory expression of bbFGF (ie, a bbFGF expression cassette).

[0046] The bacterium of the present invention has the ability to secrete and produce bbFGF. The bacterium of the present invention has the ability to secrete and produce bbFGF by having at least a bbFGF expression cassette.

[0047] "Secreting" bbFGF means transporting bbFGF outside the bacterial cell (outside the cell). Examples of outside the bacterial cell (outside the cell) include the culture medium and the bacterial cell surface. That is, for example, the secreted bbFGF may be present in the culture medium, on the bacterial cell surface, or both in the culture medium and on the bacterial cell surface. That is, "secreting" bbFGF is not limited to the case where all molecules of the bbFGF are completely free in the culture medium, but also includes the case where all molecules of the bbFGF are present on the bacterial cell surface, or where a portion of the molecules of the bbFGF are present in the culture medium and the remaining molecules are present on the bacterial cell surface.

[0048] That is, "the ability to secrete and produce bbFGF" means the ability to secrete bbFGF in the culture medium and / or on the surface of the bacteria when the bacterium of the present invention is cultured in the culture medium, and to accumulate bbFGF to the extent that it can be recovered from the culture medium and / or on the surface of the bacteria. In terms of the amount of accumulation, for example, as the amount of accumulation in the culture medium, it is preferably 10 μg / L or more, more preferably 1 mg / L or more, particularly preferably 100 mg / L or more, and further preferably 1 g / L or more. In addition, in terms of the amount of accumulation, for example, as the amount of accumulation on the surface of the bacteria, when bbFGF on the surface of the bacteria is recovered and suspended in the same amount of liquid as the culture medium, the bbFGF concentration in the suspension is preferably 10 μg / L or more, more preferably 1 mg / L or more, and particularly preferably 100 mg / L or more.

[0049] Rod-shaped bacteria are aerobic Gram-positive bacteria. Examples of rod-shaped bacteria include bacteria of the genus Corynebacterium, bacteria of the genus Brevibacterium, and bacteria of the genus Microbacterium. Advantages of using rod-shaped bacteria include: compared with filamentous fungi, yeast, and bacteria of the genus Bacillus that have been used for secretory production of proteins in the past, very little protein is originally secreted outside the bacterial body, and it can be expected that the purification process during secretory production of proteins is simplified or omitted; in addition, they grow and reproduce well in simple culture media containing sugars, ammonia, and inorganic salts, and are excellent in terms of culture media cost, culture method, and culture productivity.

[0050] Specific examples of coryneform bacteria include the following species.

[0051] Corynebacterium acetoacidophilum

[0052] Corynebacterium acetoglutamicum

[0053] Corynebacterium alkanolyticum

[0054] Corynebacterium callunae

[0055] Corynebacterium casei

[0056] Corynebacterium crenatum

[0057] Corynebacterium flavescens

[0058] Corynebacterium glutamicum

[0059] Corynebacterium lilium

[0060] Corynebacterium melassecola

[0061] Corynebacterium thermoaminogenes (Corynebacterium efficiens)

[0062] Corynebacterium herculis

[0063] Brevibacterium casei

[0064] Brevibacterium divaricatum (Corynebacterium glutamicum)

[0065] Brevibacterium flavum (Corynebacteriumglutamicum)

[0066] Brevibacterium immariophilum

[0067] Brevibacterium lactofermentum (Corynebacterium glutamicum)

[0068] Brevibacterium roseum

[0069] Brevibacterium saccharolyticum

[0070] Brevibacterium thiogenitalis

[0071] Corynebacterium ammoniagenes (Corynebacteriumstationis)

[0072] Brevibacterium album

[0073] Brevibacterium cerinum

[0074] Microbacterium ammoniaphilum

[0075] Specific examples of coryneform bacteria include the following strains.

[0076] Corynebacterium acetoaceticum ATCC 13870

[0077] Corynebacterium acetoglutamicum ATCC 15806

[0078] Corynebacterium alkanolyticum ATCC 21511

[0079] Corynebacterium sclerotium ATCC 15991

[0080] Corynebacterium casei JCM 12072

[0081] Corynebacterium scutellariae AS1.542

[0082] Corynebacterium flavum ATCC 10340

[0083] Corynebacterium glutamicum ATCC 13020, ATCC 13032, ATCC 13060, ATCC 13869, FERMBP-734

[0084] Corynebacterium lilii ATCC 15990

[0085] Corynebacterium molasses ATCC 17965

[0086] Effective Corynebacterium (Thermoammoniagenic Corynebacterium) AJ12340 (FERM BP-1539)

[0087] Corynebacterium luxuriatum ATCC 13868

[0088] Brevibacterium casei ATCC 35513

[0089] Brevibacterium difidum (Corynebacterium glutamicum) ATCC 14020

[0090] Brevibacterium flavum (Corynebacterium glutamicum) ATCC 13826, ATCC 14067, AJ12418 (FERM BP-2205)

[0091] Immature Brevibacterium ATCC 14068

[0092] Brevibacterium lactose fermentation (Corynebacterium glutamicum) ATCC 13869

[0093] Brevibacterium roseum ATCC 13825

[0094] Brevibacterium saccharolyticum ATCC 14066

[0095] Brevibacterium thiocyanobacterium ATCC 19240

[0096] Corynebacterium ammoniagenes (Corynebacterium stagnans) ATCC 6871, ATCC 6872

[0097] Brevibacterium albus ATCC 15111

[0098] Brevibacterium cereus ATCC 15112

[0099] Microbacterium ammoniaphilum ATCC 15354

[0100] It should be noted that, with respect to the genus Corynebacterium, it also includes the bacterium that was previously classified as Brevibacterium and is now classified as Corynebacterium (Int. J. Syst. Bacteriol., 41, 255 (1991)). In addition, with respect to Corynebacterium stagnation, it also includes the bacterium that was previously classified as Corynebacterium ammoniagenes and was reclassified to Corynebacterium stagnation by the base sequence analysis of 16S rRNA (Int. J. Syst. Evol. Microbiol., 60, 874-879 (2010)).

[0101] These strains, for example, can be obtained from the American type culture collection (address 12301 Parklawn Drive, Rockville, Maryland 20852 PO Box 1549, Manassas, VA 20108, United States of America) for sale. That is, the accession number corresponding to each strain is assigned, and the accession number can be used to obtain the sale (refer to http: / / www.atcc.org / ). The accession number corresponding to each strain is recorded in the catalog of the American type culture collection. In addition, these strains can be obtained, for example, from the preservation agency that preserves each strain.

[0102] In particular, Corynebacterium glutamicum AJ12036 (FERM BP-734), which was isolated as a streptomycin (Sm) resistant mutant strain from wild-type strain Corynebacterium glutamicum ATCC 13869, is predicted to have a mutation in a gene that controls a function related to protein secretion compared to its parent strain (wild-type strain), and the secretion production capacity of protein is approximately 2 to 3 times the accumulation under the most suitable culture conditions, which is very high and suitable as a host bacterium (WO2002 / 081694). AJ12036 was originally deposited as an international deposit by the Institute of Microbiology, Industrial Technology Institute (now: NITE IPOD, independent administrative agency, product evaluation technology base organization, zip code: 292-0818, address: Room 120, 2-5-8, Kazusa Kamata, Kisarazu City, Chiba Prefecture, Japan) on March 26, 1984, and was given a commission number of FERM BP-734.

[0103] In addition, the coryneform bacteria described above can be used as parent strains, and strains with improved secretory production ability of proteins can be selected by mutation or gene recombination methods and used as hosts. For example, strains with improved secretory production ability of proteins can be selected by ultraviolet irradiation or treatment with chemical mutagens such as N-methyl-N'-nitrosoguanidine.

[0104] Furthermore, if a strain modified in such a manner that the cell surface protein is not produced by such a strain is used as a host, the purification of bbFGF secreted in the culture medium or on the surface of the bacterial cell becomes easy, which is particularly preferred. Such modification can be performed by introducing a mutation into the coding region of the cell surface protein on the chromosome or its expression regulatory region by a mutation method or a gene recombination method. As a coryneform bacterium modified in such a manner that the cell surface protein is not produced, a cell surface protein PS2-deficient strain of Corynebacterium glutamicum AJ12036 (FERM BP-734), i.e., Corynebacterium glutamicum YDK010 strain (WO2002 / 081694) can be cited.

[0105] As for the bacteria of the present invention, it can be obtained by appropriately modifying the rod-shaped bacteria as described above (for example, the introduction of the bbFGF expression cassette and the introduction of other modifications as optional). That is, the bacteria of the present invention, for example, can be a modified strain derived from the rod-shaped bacteria as described above. The bacteria of the present invention, specifically, for example, can also be a modified strain derived from Corynebacterium glutamicum AJ12036 (FERM BP-734) or a modified strain derived from Corynebacterium glutamicum ATCC 13869. It should be noted that the modified strain derived from Corynebacterium glutamicum AJ12036 (FERM BP-734) is also equivalent to the modified strain derived from Corynebacterium glutamicum ATCC 13869. The modifications used to construct the bacteria of the present invention can be performed in any order.

[0106] (1-2) Gene construct for secretory expression of bbFGF and its introduction

[0107] The bacterium of the present invention has a gene construct for secretory expression of bbFGF (ie, a bbFGF expression cassette).

[0108] It is known that secretory proteins are usually translated as preproteins (also called prepeptides) or preproproteins (also called prepropeptides), and then processed to become mature proteins. Specifically, secretory proteins are usually translated as preproteins or preproproteins, and then the signal peptide as the leading part (pre-moiety) is cleaved by proteases (usually called signal peptidases) to convert them into mature proteins or proproteins. The proproteins are further cleaved by proteases to become mature proteins. Therefore, in the present invention, bbFGF can be secreted and produced using a signal peptide. It should be noted that the preproteins and preproproteins of secretory proteins are sometimes collectively referred to as "secretory protein precursors". The so-called "signal peptide" (also called "signal sequence") refers to an amino acid sequence that is present at the N-terminus of the secretory protein precursor and is usually not present in the natural mature protein.

[0109] The bbFGF expression cassette may include a promoter sequence that functions in coryneform bacteria, a nucleic acid sequence encoding a signal peptide that functions in coryneform bacteria, and a nucleic acid sequence encoding bbFGF in the 5' to 3' direction. The nucleic acid sequence encoding the signal peptide may be connected downstream of the promoter sequence in such a manner that the signal peptide is expressed under the control of the promoter. The nucleic acid sequence encoding bbFGF may be connected downstream of the nucleic acid sequence encoding the signal peptide in such a manner that bbFGF is expressed as a fusion protein with the signal peptide. The fusion protein is also referred to as "the fusion protein of the present invention". It should be noted that in the fusion protein of the present invention, the signal peptide and bbFGF may be adjacent or not adjacent. That is, "bbFGF is expressed as a fusion protein with a signal peptide" means that it is not limited to the case where bbFGF is adjacent to the signal peptide and is expressed as a fusion protein with the signal peptide, but also includes the case where bbFGF is expressed as a fusion protein with the signal peptide via other amino acid sequences. For example, as described below, in the fusion protein of the present invention, an insertion sequence such as an amino acid sequence containing Gln-Glu-Thr, an amino acid sequence for enzyme cleavage, etc. may be included between the signal peptide and bbFGF. In addition, as described below, the bbFGF finally obtained may not have a signal peptide. That is, "bbFGF is expressed as a fusion protein with a signal peptide" means that when bbFGF is expressed, a fusion protein with a signal peptide is constituted, and it is not necessary to make the bbFGF finally obtained constitute a fusion protein with a signal peptide. Nucleic acid sequences can also be referred to as "genes". For example, a nucleic acid sequence encoding bbFGF is also referred to as a "gene encoding bbFGF" or a "bbFGF gene". As a nucleic acid sequence, DNA can be cited. In addition, with respect to the bbFGF expression cassette, in order to express the fusion protein of the present invention in coryneform bacteria, an effective control sequence (operator, SD sequence, terminator, etc.) may be provided at an appropriate position in a manner that enables the function to be exerted.

[0110] The promoter used in the present invention is not particularly limited as long as it is a promoter that functions in coryneform bacteria. The so-called "promoter that functions in coryneform bacteria" refers to a promoter that has promoter activity (i.e., gene transcription activity) in coryneform bacteria. Examples of promoters that function in coryneform bacteria include those described in the "method for increasing the activity of a protein" below.

[0111] The signal peptide used in the present invention is not particularly limited as long as it is a signal peptide that functions in coryneform bacteria. The signal peptide may be a signal peptide derived from coryneform bacteria (e.g., host-derived) or a signal peptide of a heterologous origin. The so-called "signal peptide that functions in coryneform bacteria" refers to a peptide that, when connected to the N-terminus of a protein such as bbFGF, can cause coryneform bacteria to secrete the protein. Whether some signal peptides function in coryneform bacteria can be confirmed, for example, by fusing proteins such as bbFGF with the signal peptide and expressing them, and confirming whether the protein is secreted.

[0112] Examples of the signal peptide include a signal peptide that relies on the Tat system and a signal peptide that relies on the Sec system.

[0113] The "Tat system-dependent signal peptide" refers to a signal peptide recognized by the Tat system. Specifically, the "Tat system-dependent signal peptide" may be a peptide that, when linked to the N-terminus of a protein such as bbFGF, causes the secretion of the protein via the Tat system secretion machinery.

[0114] As the signal peptides that rely on the Tat system, for example, there can be mentioned the signal peptide of the TorA protein (trimethylamine-N-oxidoreductase) of Escherichia coli, the signal peptide of the SufI protein (inhibitor of ftsI) of Escherichia coli, the signal peptide of the PhoD protein (phosphodiesterase) of Bacillus subtilis, the signal peptide of the LipA protein (lipoic acid synthase) of Bacillus subtilis, and the signal peptide of the IMD protein (isomaltodextranase) of Arthrobacter globiformis. The amino acid sequences of these signal peptides are shown below.

[0115] TorA signal peptide: MNNNDLFQASRRRFLAQLGGLTVAGMLGPSLLTPRRATA (SEQ ID NO.18)

[0116] SufI signal peptide: MSLSRRQFIQASGIALCAGAVPLKASA (SEQ ID NO.19)

[0117] PhoD signal peptide: MAYDSRFDEWVQKLKEESFQNNTFDRRKFIQGAGKIAGLSLGLTIAQS (SEQ IDNO.20)

[0118] LipA ​​signal peptide: MKFVKRRTTALVTTLMLSVTSLFALQPSAKAAEH (SEQ ID NO.21)

[0119] IMD signal peptide: MMNLSRRTLLTTGSAATLAYALGMAGSAQA (SEQ ID NO.22)

[0120] The signal peptide relying on the Tat system has a twin-arginine motif. Examples of the twin-arginine motif include S / TRRXFLK (SEQ ID NO. 23) and RRX-#-# (X: naturally occurring amino acid residue; #: hydrophobic amino acid residue).

[0121] The "Sec system-dependent signal peptide" refers to a signal peptide recognized by the Sec system. Specifically, the "Sec system-dependent signal peptide" may be a peptide that, when linked to the N-terminus of a protein such as bbFGF, causes the secretion of the protein via the Sec system secretion machinery.

[0122] As the signal peptide that relies on the Sec system, for example, the signal peptide of the cell surface protein of coryneform bacteria can be enumerated.For the cell surface protein of coryneform bacteria, as mentioned above.As the cell surface protein of coryneform bacteria, PS1 and PS2 (CspB) (Japanese Patent Table Hei 6-502548) in the source of Corynebacterium glutamicum and SlpA (CspA) (Japanese Patent Laid-Open Hei 10-108675) in the source of Corynebacterium stagnation can be enumerated.The amino acid sequence of the signal peptide (PS1 signal peptide) of PS1 of Corynebacterium glutamicum is represented by SEQ IDNO.25, the amino acid sequence of the signal peptide (PS2 signal peptide) of PS2 (CspB) of Corynebacterium glutamicum is represented by SEQ IDNO.26, and the amino acid sequence of the signal peptide (SlpA signal peptide) of SlpA (CspA) of Corynebacterium stagnation is represented by SEQ IDNO.27.

[0123] As long as the signal peptide that relies on the Tat system has a twin-arginine motif and maintains the original function, it can also be a variant of the signal peptide that relies on the Tat system as described above. In addition, as long as the signal peptide that relies on the Sec system maintains the original function, it can also be a variant of the signal peptide that relies on the Sec system as described above. For variants of signal peptides and genes encoding them, the records involving conservative variants of bbFGF and bbFGF genes described below can be applied. For example, the signal peptide can be a peptide having an amino acid sequence with one or more amino acid substitutions, deletions, insertions and / or additions at one or more positions in the amino acid sequence of the signal peptide as described above. It should be noted that the "one or more" in the variant of the signal peptide is, specifically, preferably 1 to 7, more preferably 1 to 5, further preferably 1 to 3, and particularly preferably 1 to 2. It should be noted that the terms "TorA signal peptide", "SufI signal peptide", "PhoD signal peptide", "LipA signal peptide", "IMD signal peptide", "PS1 signal peptide", "PS2 signal peptide" and "SlpA signal peptide" include conservative variants thereof in addition to the peptides described in SEQ ID NOs. 18 to 22 and 25 to 27, respectively.

[0124] The so-called "maintaining the original function" of a signal peptide dependent on the Tat system means that it is recognized by the Tat system, and specifically, when linked to the N-terminus of a protein such as bbFGF, it can have the function of secreting the protein through the Tat system secretion apparatus. Whether some peptides have the function of being a signal peptide dependent on the Tat system can be confirmed, for example, by confirming that the secretory production amount of a protein to which the peptide is added to the N-terminus increases with the enhancement of the Tat system secretion apparatus, or by confirming that the secretory production amount of a protein to which the peptide is added to the N-terminus decreases with the loss of the Tat system secretion apparatus.

[0125] The so-called "maintaining the original function" of the signal peptide dependent on the Sec system means that it is recognized by the Sec system. Specifically, when it is linked to the N-terminus of a protein such as bbFGF, it can have the function of secreting the protein through the Sec system secretion apparatus. Whether some peptides have the function of being a signal peptide dependent on the Sec system can be confirmed by, for example, confirming that the secretory production of the protein to which the peptide is added to the N-terminus increases with the enhancement of the Sec system secretion apparatus, and confirming that the secretory production of the protein to which the peptide is added to the N-terminus decreases with the loss of the Sec system secretion apparatus.

[0126] As for the signal peptide, it is usually cut by a signal peptidase when the translation product is secreted outside the bacteria. That is, the bbFGF finally obtained may not have a signal peptide. It should be noted that the gene encoding the signal peptide can be used as a natural gene, or it can be modified in a manner that has the most appropriate codon according to the codon usage frequency of the host used.

[0127] In the bbFGF expression cassette, a nucleic acid sequence encoding an amino acid sequence containing Gln-Glu-Thr can be inserted between the nucleic acid sequence encoding the signal peptide and the nucleic acid sequence encoding bbFGF (WO2013 / 062029). It should be noted that the "amino acid sequence containing Gln-Glu-Thr" is also referred to as the "insertion sequence used in the present invention". As the insertion sequence used in the present invention, the amino acid sequence containing Gln-Glu-Thr described in WO2013 / 062029 can be cited. The insertion sequence used in the present invention can be used appropriately in combination with a signal peptide that depends on the Sec system.

[0128] The insertion sequence used in the present invention is preferably a sequence comprising 3 or more amino acid residues starting from the N-terminus of the mature protein of the cell surface protein CspB of coryneform bacteria (hereinafter also referred to as "mature CspB" or "CspB mature protein"). The "sequence comprising 3 or more amino acid residues starting from the N-terminus" refers to an amino acid sequence starting from the amino acid residue at position 1 of the N-terminus to the amino acid residue at position 3 or more.

[0129] For the cell surface protein CspB of coryneform bacteria, it is described as follows. As CspB, specifically, for example, CspB of Corynebacterium glutamicum ATCC13869, CspB of 28 strains of Corynebacterium glutamicum described below, and their variants can be cited. In the amino acid sequence of CspB of Corynebacterium glutamicum ATCC13869 represented by SEQ ID NO.11, the amino acid residues at positions 1 to 30 are equivalent to the signal peptide, and the amino acid residues at positions 31 to 499 are equivalent to the CspB mature protein. SEQ ID NO.28 represents the amino acid sequence of the CspB mature protein of Corynebacterium glutamicum ATCC13869 excluding the 30 amino acid residues of the signal peptide portion. It should be noted that in the mature CspB of Corynebacterium glutamicum ATCC13869, the amino acid residues at positions 1 to 3 of the N-terminus are equivalent to Gln-Glu-Thr.

[0130] The insertion sequence used in the present invention is preferably an amino acid sequence starting from the amino acid residue at position 1 of mature CspB to any one of the amino acid residues at positions 3 to 50. The insertion sequence used in the present invention is more preferably an amino acid sequence starting from the amino acid residue at position 1 of mature CspB to any one of the amino acid residues at positions 3 to 8, 17, and 50. The insertion sequence used in the present invention is particularly preferably an amino acid sequence starting from the amino acid residue at position 1 of mature CspB to any one of the amino acid residues at positions 4, 6, 17, and 50.

[0131] The insertion sequence used in the present invention is preferably, for example, an amino acid sequence selected from the following amino acid sequences (A) to (H).

[0132] (A) Gln-Glu-Thr

[0133] (B) Gln-Glu-Thr-Xaa1

[0134] (C) Gln-Glu-Thr-Xaa1-Xaa2

[0135] (D) Gln-Glu-Thr-Xaa1-Xaa2-Xaa3

[0136] (E) Amino acid sequence with amino acid residues 4 to 7 of mature CspB added to Gln-Glu-Thr

[0137] (F) Amino acid sequence with amino acid residues 4 to 8 of mature CspB added to Gln-Glu-Thr

[0138] (G) Amino acid sequence with amino acid residues 4 to 17 of mature CspB added to Gln-Glu-Thr

[0139] (H) Amino acid sequence with amino acid residues 4 to 50 of mature CspB added to Gln-Glu-Thr

[0140] In the amino acid sequences of (A) to (H), Xaa1 is Asn, Gly, Thr, Pro or Ala, Xaa2 is Pro, Thr or Val, and Xaa3 is Thr or Tyr. In addition, in the amino acid sequences of (A) to (H), the so-called "amino acid residues at positions 4 to X of mature CspB are added to Gln-Glu-Thr" means that amino acid residues from positions 4 to X of the N-terminus of mature CspB are added to Thr of Gln-Glu-Thr. It should be noted that, usually, the amino acid residues at positions 1 to 3 of the N-terminus of mature CspB are Gln-Glu-Thr. In this case, the so-called "amino acid sequence having amino acid residues at positions 4 to X of mature CspB added to Gln-Glu-Thr" has the same meaning as the amino acid sequence containing amino acid residues at positions 1 to X of mature CspB.

[0141] In addition, with regard to the insertion sequence used in the present invention, specifically, for example, it is preferably an amino acid sequence selected from Gln-Glu-Thr-Asn-Pro-Thr (SEQ ID NO.32), Gln-Glu-Thr-Gly-Thr-Tyr (SEQ ID NO.33), Gln-Glu-Thr-Thr-Val-Thr (SEQ ID NO.34), Gln-Glu-Thr-Pro-Val-Thr (SEQ ID NO.35) and Gln-Glu-Thr-Ala-Val-Thr (SEQ ID NO.36).

[0142] The so-called "amino acid residue at position X of mature CspB" means an amino acid residue equivalent to the amino acid residue at position X in SEQ ID NO. 28. In any amino acid sequence of mature CspB, whether a certain amino acid residue is "an amino acid residue equivalent to the amino acid residue at position X in SEQ ID NO. 28" can be determined by aligning the amino acid sequence of any mature CspB with the amino acid sequence of SEQ ID NO. 28.

[0143] "Bovine basic fibroblast growth factor (bbFGF)" may refer to basic fibroblast growth factor derived from bovine. "Bovine" for bbFGF may refer to organisms of the genus Bos. Examples of organisms of the genus Bos include domestic cattle (Bos taurus). The base sequence of the bbFGF gene and the amino acid sequence of bbFGF can be obtained from public databases such as NCBI, patent documents and other technical documents. The base sequence of the bbFGF gene of domestic cattle (modified in consideration of the codon usage frequency of Corynebacterium glutamicum) and the amino acid sequence of bbFGF encoded by the gene are shown as SEQ ID NOs. 45 and 46, respectively.

[0144] The bbFGF gene may be, for example, a gene having the base sequence of the bbFGF gene described above (for example, the base sequence represented by SEQ ID NO.45). The bbFGF may be, for example, a protein having the amino acid sequence of the bbFGF described above (for example, the amino acid sequence represented by SEQ ID NO.46). It should be noted that the expression "a gene or protein has a base sequence or an amino acid sequence" may mean that the gene or protein includes the base sequence or the amino acid sequence, and may also include the case where the gene or protein is composed of the base sequence or the amino acid sequence, unless otherwise specified.

[0145] The bbFGF gene can be, for example, a variant of a gene having the base sequence of the bbFGF gene as described above. bbFGF can be, for example, a variant of a protein having the amino acid sequence of bbFGF as described above. The variant is not particularly limited as long as it has the desired function. The variant can be, for example, a conservative variant. "Conservative variant" refers to a variant that retains the original function. As variants such as conservative variants, for example, homologs and artificially modified forms of genes and proteins having the base sequence of the bbFGF gene as described above and the amino acid sequence of bbFGF as described above can be cited. As homologs, in the case of bbFGF, homologs possessed by organisms of the genus Bos can be cited. It should be noted that the protein determined by the biological species of origin is not limited to the protein itself found in the biological species, but also includes proteins having the amino acid sequence of proteins found in the biological species and their variants. Variants may be found in the biological species or not. That is, for example, "bbFGF" is not limited to basic fibroblast growth factor itself found in organisms of the genus Bos, but also includes proteins having the amino acid sequence of basic fibroblast growth factor found in organisms of the genus Bos and variants thereof.

[0146] "Maintaining the original function" means that the variant of a gene or protein has a function (e.g., activity or property) corresponding to the function (e.g., activity or property) of the original gene or protein. "Maintaining the original function" of a gene means that the variant of the gene encodes a protein that retains the original function. "Maintaining the original function" of bbFGF means that the variant of bbFGF has the function of promoting the proliferation of animal cells.

[0147] Hereinafter, conservative variants and the like are shown below.

[0148] The bbFGF gene and bbFGF homologs can be easily obtained from public databases by, for example, BLAST search or FASTA search using the above-described bbFGF gene base sequence or the above-described bbFGF amino acid sequence as a query sequence. In addition, bbFGF gene homologs can be obtained by, for example, PCR using the chromosomes of various organisms as templates and oligonucleotides prepared based on the above-described bbFGF gene base sequence as primers.

[0149] The bbFGF gene may be a gene encoding a protein having an amino acid sequence in which one or more amino acids are substituted, deleted, inserted and / or added at one or more positions in the amino acid sequence of bbFGF as described above. For example, the N-terminus and / or C-terminus of the encoded protein may be extended or shortened. It should be noted that the "one or more" varies depending on the position and type of the amino acid residues in the three-dimensional structure of the protein, and specifically, for example, means 1 to 50, 1 to 40, 1 to 30, preferably 1 to 20, more preferably 1 to 10, further preferably 1 to 5, and particularly preferably 1 to 3.

[0150] The substitution, deletion, insertion or addition of one or more amino acids can be a conservative mutation that maintains the original function of the protein. The representative of conservative mutations is conservative substitution. The so-called conservative substitution refers to a mutation in which Phe, Trp, and Tyr are mutually substituted when the substitution site is an aromatic amino acid; a mutation in which Leu, Ile, and Val are mutually substituted when the substitution site is a hydrophobic amino acid; a mutation in which Gln and Asn are mutually substituted when the substitution site is a polar amino acid; a mutation in which Lys, Arg, and His are mutually substituted when the substitution site is a basic amino acid; a mutation in which Asp and Glu are mutually substituted when the substitution site is an acidic amino acid; and a mutation in which Ser and Thr are mutually substituted when the substitution site is a hydroxyl-containing amino acid. Specific examples of substitutions considered as conservative substitutions include substitutions of Ala with Ser or Thr, substitutions of Arg with Gln, His or Lys, substitutions of Asn with Glu, Gln, Lys, His or Asp, substitutions of Asp with Asn, Glu or Gln, substitutions of Cys with Ser or Ala, substitutions of Gln with Asn, Glu, Lys, His, Asp or Arg, substitutions of Glu with Gly, Asn, Gln, Lys or Asp, substitutions of Gly with Pro, and substitutions of His with Asn, Lys, Gln, Arg or Ty. r, Ile is substituted with Leu, Met, Val or Phe, Leu is substituted with Ile, Met, Val or Phe, Lys is substituted with Asn, Glu, Gln, His or Arg, Met is substituted with Ile, Leu, Val or Phe, Phe is substituted with Trp, Tyr, Met, Ile or Leu, Ser is substituted with Thr or Ala, Thr is substituted with Ser or Ala, Trp is substituted with Phe or Tyr, Tyr is substituted with His, Phe or Trp, and Val is substituted with Met, Ile or Leu. In addition, such amino acid substitutions, deletions, insertions, additions or inversions include those produced by naturally occurring mutations (mutants or variants) based on individual differences of organisms from which genes are derived, species differences, etc.

[0151] In addition, the bbFGF gene may be a gene encoding a protein having an amino acid sequence that is, for example, 50% or more, 65% or more, 80% or more, preferably 90% or more, more preferably 95% or more, further preferably 97% or more, and particularly preferably 99% or more identical to the entire amino acid sequence of bbFGF shown above.

[0152] In addition, the bbFGF gene may be a gene, such as DNA, that hybridizes under stringent conditions with a probe prepared from the base sequence of the bbFGF gene as described above, for example, a complementary sequence to the entire or a part of the base sequence of the bbFGF gene as described above. The so-called "stringent conditions" refer to conditions under which specific hybridization is formed and non-specific hybridization is not formed. As an example, DNAs with high identity, such as DNAs with identity of 50% or more, 65% or more, 80% or more, preferably 90% or more, more preferably 95% or more, further preferably 97% or more, and particularly preferably 99% or more, hybridize with each other, while DNAs with low identity do not hybridize with each other; or conditions for washing at a salt concentration and temperature equivalent to the usual Southern blot hybridization washing conditions, i.e., 60°C, 1×SSC, 0.1% SDS, preferably 60°C, 0.1×SSC, 0.1% SDS, more preferably 68°C, 0.1×SSC, 0.1% SDS, once, preferably 2 to 3 times.

[0153] As described above, the probe used for the hybridization may be a part of the complementary sequence of the gene. Such a probe can be prepared by PCR using an oligonucleotide prepared based on the base sequence of the bbFGF gene as described above as a primer and a DNA fragment containing the gene as a template. For example, a DNA fragment of about 300 bp in length can be used as a probe. When a DNA fragment of about 300 bp in length is used as a probe, the conditions for washing the hybridization may include 50°C, 2×SSC, and 0.1% SDS.

[0154] In addition, since the degeneracy of codons varies depending on the host, any codon in the bbFGF gene can be replaced with an equivalent codon. That is, the bbFGF gene can be a variant of the bbFGF gene described above based on the degeneracy of the gene encoding. For example, the bbFGF gene can be modified so as to have the most appropriate codons according to the codon usage frequency of the host used.

[0155] It should be noted that the so-called "identity" between amino acid sequences refers to the identity between amino acid sequences calculated by blastp using the default Scoring Parameters (Matrix: BLOSUM62; Gap Costs: Existence = 11, Extension = 1; Compositional Adjustments: Conditional compositional score matrix adjustment). In addition, the so-called "identity" between base sequences refers to the identity between base sequences calculated by blastn using the default Scoring Parameters (Match / Mismatch Scores = 1, -2; Gap Costs = Linear).

[0156] The description concerning the bbFGF and variants of the bbFGF gene may be applied to other proteins and base sequences encoding the same.

[0157] The bbFGF expression cassette may further include a nucleic acid sequence encoding an amino acid sequence for enzyme cleavage between the nucleic acid sequence encoding the amino acid sequence comprising Gln-Glu-Thr and the nucleic acid sequence encoding bbFGF. By inserting the amino acid sequence for enzyme cleavage into the fusion protein of the present invention, the expressed fusion protein can be cleaved by enzyme catalysis to obtain bbFGF.

[0158] The amino acid sequence for enzymatic cleavage is not particularly limited as long as it is a sequence recognized and cleaved by an enzyme that hydrolyzes peptide bonds, and a sequence that can be used can be appropriately selected according to the amino acid sequence of bbFGF. The nucleic acid sequence encoding the amino acid sequence for enzymatic cleavage can be appropriately designed based on the amino acid sequence. For example, the nucleic acid sequence encoding the amino acid sequence for enzymatic cleavage can be designed in a manner that has the most suitable codons according to the codon usage frequency of the host.

[0159] The amino acid sequence used for enzymatic cleavage is preferably a recognition sequence of a protease with high substrate specificity. As such an amino acid sequence, specifically, for example, the recognition sequence of Factor Xa protease and the recognition sequence of proTEV protease can be cited. Factor Xa protease recognizes the amino acid sequence of Ile-Glu-Gly-Arg (=IEGR) (SEQ ID NO.37) in the protein, and proTEV protease recognizes the amino acid sequence of Glu-Asn-Leu-Tyr-Phe-Gln (=ENLYFQ) (SEQ ID NO.38) in the protein, thereby specifically cutting off the C-terminal side of each sequence.

[0160] The N-terminal region of the bbFGF finally obtained may be the same as the natural protein or different from the natural protein. For example, the N-terminal region of the bbFGF finally obtained may have one or more extra amino acids added or deleted compared to the natural protein. It should be noted that the "one or more" mentioned above varies depending on the full length and structure of bbFGF, and specifically, it is preferably 1 to 20, more preferably 1 to 10, further preferably 1 to 5, and particularly preferably 1 to 3.

[0161] The method for introducing the bbFGF expression cassette into coryneform bacteria is not particularly limited. "Introduction of the bbFGF expression cassette" means that the gene construct is maintained in the host. "Introduction of the bbFGF expression cassette" is not limited to the case where the previously constructed gene construct is introduced into the host, but also includes the case where at least the bbFGF gene is introduced into the host and the gene construct is constructed in the host. In the bacteria of the present invention, the bbFGF expression cassette may be present on a vector that autonomously proliferates outside the chromosome, such as a plasmid, or may be introduced into the chromosome. The introduction of the bbFGF expression cassette can be carried out in the same manner as the introduction of the gene in the "method for increasing the activity of a protein" described below.

[0162] The bbFGF expression cassette can be introduced into a host, for example, using a vector containing the gene construct. For example, an expression vector of the gene construct can be constructed by connecting the bbFGF expression cassette to a vector, and the host can be transformed with the expression vector to introduce the gene construct into the host. In addition, for example, when the vector has a promoter that functions in coryneform bacteria, an expression vector of the bbFGF expression cassette can be constructed by connecting a base sequence encoding the fusion protein of the present invention downstream of the promoter. The vector is not particularly limited as long as it can replicate autonomously in coryneform bacteria. The vectors that can be used in coryneform bacteria are as described above.

[0163] In addition, the bbFGF expression cassette can be introduced into the host's chromosome using, for example, a transposon such as an artificial transposon. When a transposon is used, the bbFGF expression cassette is introduced into the chromosome by homologous recombination or its own transfer ability. In addition, the bbFGF expression cassette can be introduced into the host's chromosome by an introduction method utilizing homologous recombination. As an introduction method utilizing homologous recombination, for example, methods using linear DNA, a plasmid containing a temperature-sensitive replication origin, a plasmid capable of conjugative transfer, or a suicide vector that does not have a replication origin that functions in the host can be cited. In addition, at least the bbFGF gene can be introduced into the chromosome to construct the bbFGF expression cassette on the chromosome. In this case, part or all of the constituent elements of the bbFGF expression cassette other than the bbFGF gene may originally exist on the host's chromosome. Specifically, for example, the promoter sequence originally present on the chromosome of the host and the nucleic acid sequence encoding a signal peptide linked to the downstream of the promoter sequence can be used as they are, and only the gene linked to the downstream of the nucleic acid sequence encoding the signal peptide can be replaced with the bbFGF gene, thereby constructing a bbFGF expression cassette on the chromosome to construct the bacterium of the present invention. The introduction of a part of the bbFGF expression cassette such as the bbFGF gene into the chromosome can be carried out in the same manner as the introduction of the bbFGF expression cassette into the chromosome.

[0164] The bbFGF expression cassette and its constituent elements (promoter sequence, nucleic acid sequence encoding signal peptide, nucleic acid sequence encoding bbFGF, etc.) can be obtained, for example, by cloning. Specifically, for example, the bbFGF gene can be obtained by cloning from an organism having bbFGF, and modified by introducing a base sequence encoding a signal peptide, introducing a promoter sequence, etc., to obtain the bbFGF expression cassette. In addition, the bbFGF expression cassette and its constituent elements can be obtained by chemical synthesis (Gene, 60 (1), 115-127 (1987)). The obtained gene construct and its constituent elements can be used as they are or with appropriate modifications.

[0165] The method for introducing the bbFGF expression cassette into coryneform bacteria is not particularly limited, and commonly used methods such as the protoplast method (Gene, 39, 281-286 (1985)), the electroporation method (Bio / Technology, 7, 1067-1070 (1989)), and the electric pulse method (Japanese Patent Application Laid-Open No. 2-207791) can be used.

[0166] (1-3) Other properties

[0167] As long as the bacteria of the present invention can secrete and produce bbFGF, they can have the desired properties. For example, the activity of the cell surface protein in the bacteria of the present invention can be reduced (WO2013 / 065869, WO2013 / 065772, WO2013 / 118544, WO2013 / 062029). In addition, the bacteria of the present invention can be modified in a manner that reduces the activity of penicillin binding protein (WO2013 / 065869). In addition, the bacteria of the present invention can be modified in a manner that increases the expression of genes encoding metallopeptidase (WO2013 / 065772). In addition, the bacteria of the present invention can be modified in a manner that has a mutant ribosomal protein S1 gene (mutant rpsA gene) (WO2013 / 118544). In addition, the bacteria of the present invention can be modified in a manner that has a mutant phoS gene (WO2016 / 171224). In addition, the bacteria of the present invention can be modified in a manner that reduces the activity of the RegX3 protein (WO2018 / 074578). In addition, the bacteria of the present invention can be modified in a manner that reduces the activity of the HrrSA system (WO2018 / 074579). In addition, the bacteria of the present invention can be modified in a manner that increases the activity of the Tat system secretion apparatus. In addition, the bacteria of the present invention can be modified in a manner that reduces the activity of protein O-mannosyltransferase (Protein O-mannosyltransferase; PMT) (Martina Mahne et al., The Corynebacterium glutamicum gene pmt encoding a glycosyltransferase related to eukaryotic protein-O-mannosyltransferases isessential for glycosylation of the resuscitation promoting factor (Rpf2) and other secreted proteins. FEMS Microbiol Lett. 2006 Jun; 259 (2): 226-33.). These properties or modifications can be utilized alone or in appropriate combination.

[0168] (1-3-1) Introduction of mutant phoS gene

[0169] The bacterium of the present invention may be modified so as to maintain a mutant phoS gene. "Maintaining a mutant phoS gene" may also be referred to as "having a mutant phoS gene" or "having a mutation in the phoS gene". In addition, "maintaining a mutant phoS gene" may also be referred to as "having a mutant PhoS protein" or "having a mutation in the PhoS protein".

[0170] Hereinafter, the phoS gene and the PhoS protein are described. The phoS gene is a gene encoding the PhoS protein as a sensor kinase of the PhoRS system. The PhoRS system is a two-component control system that causes a response to a lack of phosphate in the environment. The PhoRS system includes a sensor kinase PhoS encoded by the phoS gene and a response regulator PhoR encoded by the phoR gene.

[0171] A PhoS protein having a "specific mutation" is also referred to as a "mutant PhoS protein", and a gene encoding it is also referred to as a "mutant phoS gene". In other words, a "mutant phoS gene" is a phoS gene having a "specific mutation". In addition, a PhoS protein not having a "specific mutation" is also referred to as a "wild-type PhoS protein", and a gene encoding it is also referred to as a "wild-type phoS gene". In other words, a "wild-type phoS gene" is a phoS gene not having a "specific mutation". It should be noted that the "wild type" here is a convenient description to distinguish it from the "mutant type", and is not limited to a naturally obtained one as long as it does not have a "specific mutation". The "specific mutation" is described below.

[0172] As the wild-type phoS gene, for example, phoS genes of coryneform bacteria can be cited. As the phoS gene of coryneform bacteria, specifically, for example, phoS genes of Corynebacterium glutamicum YDK010 strain, Corynebacterium glutamicum ATCC13032 strain, Corynebacterium glutamicum ATCC14067 strain, Corynebacterium sphaeroides, Corynebacterium sphaeroides and Corynebacterium efficacious can be cited. The base sequence of the phoS gene of Corynebacterium glutamicum YDK010 strain is represented by SEQ ID NO. 1. In addition, the amino acid sequences of the wild-type PhoS proteins encoded by these phoS genes are represented by SEQ ID NOs. 2 to 7, respectively.

[0173] The wild-type phoS gene may be a variant of the wild-type phoS gene as described above, as long as it does not have a "specific mutation" and maintains its original function. Similarly, the wild-type PhoS protein may be a variant of the wild-type PhoS protein as described above, as long as it does not have a "specific mutation" and maintains its original function. That is, the term "wild-type phoS gene" is not limited to the wild-type phoS gene as described above, and includes conservative variants thereof that do not have a "specific mutation". Similarly, the term "wild-type PhoS protein" is not limited to the wild-type PhoS protein as described above, and includes conservative variants thereof that do not have a "specific mutation". With respect to the wild-type PhoS protein and the variants of the wild-type phoS gene, the descriptions concerning the conservative variants of the bbFGF gene and bbFGF may be applied. For example, the wild-type phoS gene may be a gene encoding a protein having an amino acid sequence in which one or more amino acids are substituted, deleted, inserted, and / or added at one or more positions in the amino acid sequence, as long as it does not have a "specific mutation" and maintains its original function. In addition, for example, the wild-type phoS gene can be a gene encoding a protein having an amino acid sequence that is 80% or more, preferably 90% or more, more preferably 95% or more, further preferably 97% or more, and particularly preferably 99% or more identical to the entire amino acid sequence, as long as it does not have a "specific mutation" and maintains its original function.

[0174] It should be noted that the so-called "maintaining the original function" may mean that the variant of the protein has the function of being a PhoS protein in the wild-type PhoS protein (for example, the function of the protein composed of the amino acid sequence represented by SEQ ID NO. 2 to 7). In addition, the so-called "maintaining the original function" may mean that the variant of the protein has the function of being a sensor kinase of the PhoRS system in the wild-type PhoS protein. That is, the so-called "function as a PhoS protein" may be, specifically, the function of being a sensor kinase of the PhoRS system. The so-called "function as a sensor kinase of the PhoRS system" may be, specifically, the function of conjugating with the response regulator, that is, the PhoR protein, and causing a response to the lack of phosphate in the environment. The so-called "function as a sensor kinase of the PhoRS system" may be, more specifically, the function of sensing the lack of phosphate in the environment and performing self-phosphorylation, and activating the PhoR protein by transferring the phosphate group.

[0175] Whether a variant of the PhoS protein has a function as a sensor kinase of the PhoRS system can be determined, for example, by introducing a gene encoding the variant into a phoS gene-deficient strain of a coryneform bacterium and confirming whether the responsiveness to phosphate deficiency is complemented. Complementation of the responsiveness to phosphate deficiency can be detected, for example, as an increase in growth and proliferation under phosphate deficiency conditions or as an induction of expression of a gene known to be induced to be expressed under phosphate deficiency conditions (J. Bacteriol., 188, 724-732 (2006)). As a phoS gene-deficient strain of a coryneform bacterium, for example, a phoS gene-deficient strain of Corynebacterium glutamicum YDK010 strain and a phoS gene-deficient strain of Corynebacterium glutamicum ATCC13032 strain can be used.

[0176] In the wild-type PhoS protein, the autophosphorylated histidine residue is preferably preserved. That is, the conservative mutation is preferably generated in an amino acid residue other than the autophosphorylated histidine residue. The so-called "autophosphorylated histidine residue" refers to the histidine residue at position 276 of the wild-type PhoS protein. In addition, the wild-type PhoS protein preferably has, for example, the conserved sequence of the wild-type PhoS protein as described above. That is, the conservative mutation is preferably generated in, for example, an amino acid residue that is not conserved in the wild-type PhoS protein as described above.

[0177] The mutant PhoS protein has a "specific mutation" in the amino acid sequence of the wild-type PhoS protein as described above.

[0178] In other words, the mutant PhoS protein may be identical to the wild-type PhoS protein or a conservative variant thereof as described above, except for the "specific mutation". Specifically, for example, the mutant PhoS protein may be a protein having an amino acid sequence represented by SEQ ID NOs. 2 to 7, except for the "specific mutation". Specifically, for example, the mutant PhoS protein may be a protein having an amino acid sequence including substitution, deletion, insertion and / or addition of one or more amino acids in the amino acid sequence represented by SEQ ID NOs. 2 to 7, except for the "specific mutation". Specifically, for example, the mutant PhoS protein may be a protein having an identity of 80% or more, preferably 90% or more, more preferably 95% or more, more preferably 97% or more, and particularly preferably 99% or more with respect to the amino acid sequence represented by SEQ ID NOs. 2 to 7, except for the "specific mutation".

[0179] In other words, the mutant PhoS protein may be a variant having a "specific mutation" in the wild-type PhoS protein as described above, and further comprising a conservative mutation at a position other than the "specific mutation". Specifically, for example, the mutant PhoS protein may be a protein having an amino acid sequence having a "specific mutation" in the amino acid sequence represented by SEQ ID NOs. 2 to 7, and further comprising substitution, deletion, insertion and / or addition of one or more amino acids at a position other than the "specific mutation".

[0180] The mutant phoS gene is not particularly limited as long as it encodes the mutant PhoS protein as described above.

[0181] Hereinafter, the "specific mutation" possessed by the mutant PhoS protein will be described.

[0182] The "specific mutation" is not particularly limited as long as it modifies the amino acid sequence of the wild-type PhoS protein as described above and is effective for secretory production of a heterologous protein such as bbFGF.

[0183] The "specific mutation" is preferably a mutation that increases the secretion production of heterologous proteins such as bbFGF. The so-called "increasing the secretion production of heterologous proteins" means that the coryneform bacteria (modified strain) modified in a manner having a mutant phoS gene can secrete and produce a larger amount of heterologous proteins compared to the unmodified strain. The so-called "unmodified strain" refers to a control strain that does not have a mutation in the phoS gene, that is, a control strain that does not have a mutant phoS gene, for example, it can be a wild-type strain or a parent strain. The so-called "secretion and production of a larger amount of heterologous proteins compared to the unmodified strain" means that as long as the secretion production of heterologous proteins is increased compared to the unmodified strain, there is no particular limitation. For example, as the accumulation amount in the culture medium and / or the bacterial surface, the amount of heterologous proteins that can be secreted and produced is preferably 1.1 times or more of the unmodified strain, more preferably 1.2 times or more, more preferably 1.3 times or more, more preferably 2 times or more, and particularly preferably 5 times or more. In addition, the term "secretory production of a heterologous protein in a larger amount than that of an unmodified strain" may mean that when the culture supernatant of an unmodified strain without concentration is subjected to SDS-PAGE and stained with CBB, the heterologous protein cannot be detected, but when the culture supernatant of a modified strain without concentration is subjected to SDS-PAGE and stained with CBB, the heterologous protein can be detected. It should be noted that the term "increasing the secretory production of a heterologous protein" means that it is not necessary to increase the secretory production of all heterologous proteins, but only to increase the secretory production of a heterologous protein set as a target for secretory production. Specifically, the term "increasing the secretory production of a heterologous protein" may mean, for example, increasing the secretory production of a heterologous protein as described in the Examples.

[0184] Whether a certain mutation is a mutation that increases the secretory production amount of a heterologous protein such as bbFGF can be confirmed, for example, by preparing a modified strain that has been modified to have a gene encoding a PhoS protein having the mutation based on a strain belonging to a coryneform bacterium, quantifying the amount of the heterologous protein secreted and produced when the modified strain is cultured in a medium, and comparing the amount of the heterologous protein secreted and produced when the strain before modification (unmodified strain) is cultured in a medium.

[0185] As a change in the amino acid sequence, the replacement of amino acid residues is preferred. That is, the "specific mutation" is preferably a replacement of any amino acid residue in the wild-type PhoS protein with other amino acid residues. The amino acid residue replaced according to the "specific mutation" can be one residue, or it can be two residues or a combination of two or more. The amino acid residue replaced according to the "specific mutation" is preferably an amino acid residue other than the self-phosphorylated histidine residue. The amino acid residue replaced according to the "specific mutation" is more preferably an amino acid residue of the HisKA domain other than the self-phosphorylated histidine residue. The so-called "self-phosphorylated histidine residue" refers to the histidine residue at position 276 of the wild-type PhoS protein. The so-called "HisKA domain" refers to the region containing amino acid residues at positions 266 to 330 of the wild-type PhoS protein. The amino acid residue replaced according to the "specific mutation" is particularly preferably a tryptophan residue (W302) at position 302 of the wild-type PhoS protein.

[0186] In the above mutation, the amino acid residue after substitution includes K (Lys), R (Arg), H (His), A (Ala), V (Val), L (Leu), I (Ile), G (Gly), S (Ser), T (Thr), P (Pro), F (Phe), W (Trp), Y (Tyr), C (Cys), M (Met), D (Asp), E (Glu), N (Asn), Q (Gln), and amino acid residues other than the original amino acid residues. As the amino acid residue after substitution, for example, an amino acid residue that increases the secretory production amount of a heterologous protein such as bbFGF can be selected.

[0187] When W302 is substituted, the amino acid residue after the substitution includes amino acid residues other than aromatic amino acids and histidine. Specifically, “amino acid residues other than aromatic amino acids and histidine” include K (Lys), R (Arg), A (Ala), V (Val), L (Leu), I (Ile), G (Gly), S (Ser), T (Thr), P (Pro), C (Cys), M (Met), D (Asp), E (Glu), N (Asn), and Q (Gln). More specifically, “amino acid residues other than aromatic amino acids and histidine” include K (Lys), A (Ala), V (Val), S (Ser), C (Cys), M (Met), D (Asp), and N (Asn).

[0188] It should be noted that the so-called "specific mutation" in the phoS gene refers to a mutation in the base sequence that causes the above-mentioned "specific mutation" to occur in the encoded PhoS protein.

[0189] The "amino acid residue at position X of the wild-type PhoS protein" refers to an amino acid residue equivalent to the amino acid residue at position X of SEQ ID NO.2. For example, "W302" refers to an amino acid residue equivalent to the tryptophan residue at position 302 of SEQ ID NO.2. The position of the amino acid residue indicates a relative position, and its absolute position may change due to deletion, insertion, addition, etc. of an amino acid. For example, in the wild-type PhoS protein comprising the amino acid sequence represented by SEQ ID NO.2, when one amino acid residue is deleted or inserted at a position closer to the N-terminal side than position X, the amino acid residue at the original position X, the amino acid residue at position X-1 or position X+1, respectively, counted from the N-terminal, is regarded as the "amino acid residue at position X of the wild-type PhoS protein". Specifically, for example, in the amino acid sequence of the wild-type PhoS protein represented by SEQ ID NOs. 2 to 7, "W302" refers to the tryptophan residues at positions 302, 302, 302, 321, 275, and 286, respectively. Furthermore, in the amino acid sequence of the wild-type PhoS protein represented by SEQ ID NOs. 2 to 7, "the histidine residue at position 276 of the wild-type PhoS protein (autophosphorylated histidine residue)" refers to the histidine residues at positions 276, 276, 276, 295, 249, and 260, respectively. In addition, in the amino acid sequence of the wild-type PhoS protein represented by SEQ ID NOs. 2 to 7, the so-called "region comprising amino acid residues 266 to 330 of the wild-type PhoS protein (HisKA domain)" refers to the regions comprising amino acid residues 266 to 330, 266 to 330, 266 to 330, 285 to 349, 239 to 303, and 250 to 314, respectively.

[0190] It should be noted that "W302" as used herein is generally a tryptophan residue, but may not be a tryptophan residue. That is, in the case where the wild-type PhoS protein has an amino acid sequence other than the amino acid sequence represented by SEQ ID NOs. 2 to 7, "W302" may not be a tryptophan residue. Therefore, for example, "a mutation in which W302 is substituted with a cysteine ​​residue" is not limited to a mutation in which the tryptophan residue is substituted with a cysteine ​​residue when "W302" is a tryptophan residue, but also includes a mutation in which the amino acid residue is substituted with a cysteine ​​residue when "W302" is K (Lys), R (Arg), H (His), A (Ala), V (Val), L (Leu), I (Ile), G (Gly), S (Ser), T (Thr), P (Pro), F (Phe), Y (Tyr), M (Met), D (Asp), E (Glu), N (Asn) or Q (Gln). The same applies to other mutations.

[0191] In the amino acid sequence of any PhoS protein, which amino acid residue is "the amino acid residue corresponding to the amino acid residue at position X in SEQ ID NO. 2" can be determined by aligning the amino acid sequence of the arbitrary PhoS protein with the amino acid sequence of SEQ ID NO. 2. The alignment can be performed, for example, using a known gene analysis software. Specific examples of the software include DNASIS manufactured by HITACHISOLUTIONS and GENETYX manufactured by GENETYX (Elizabeth C. Tyler et al., Computers and Biomedical Research, 24(1), 72-96, 1991; Barton GJ et al., Journal of molecular biology, 198(2), 327-37. 1987).

[0192] The mutant phoS gene can be obtained, for example, by modifying the wild-type phoS gene so that the encoded PhoS protein has the "specific mutation". The wild-type phoS gene as the source of modification can be obtained, for example, by cloning from an organism having the wild-type phoS gene or by chemical synthesis. In addition, the mutant phoS gene can be obtained without using the wild-type phoS gene. For example, the mutant phoS gene can be directly obtained by chemical synthesis. The obtained mutant phoS gene can be further modified and used.

[0193] The modification of gene can be carried out by known methods. For example, by site-specific mutagenesis, target mutation is introduced into the target site of DNA. As site-specific mutagenesis, methods using PCR (Higuchi, R., 61, in PCR technology, Erlich, HA Eds., Stockton press (1989); Carter, P., Meth. in Enzymol., 154, 382 (1987)), methods using bacteriophage (Kramer, W. and Frits, HJ, Meth. in Enzymol., 154, 350 (1987); Kunkel, TA et al., Meth. in Enzymol., 154, 367 (1987)) can be cited.

[0194] Hereinafter, a method for modifying a coryneform bacterium so as to have a mutant phoS gene will be described.

[0195] Modification of coryneform bacteria to have a mutant phoS gene can be achieved by introducing a mutant phoS gene into coryneform bacteria. In addition, modification of coryneform bacteria to have a mutant phoS gene can be achieved by introducing the above-mentioned "specific mutation" into the phoS gene on the chromosome of coryneform bacteria. Introduction of mutations into genes on chromosomes can be achieved by natural mutations, mutagen treatment (mutagenesis treatment) or genetic engineering methods.

[0196] The method for introducing the mutant phoS gene into coryneform bacteria is not particularly limited. In the bacteria of the present invention, the mutant phoS gene can be expressed under the control of a promoter that functions in coryneform bacteria. The promoter can be a promoter derived from the host or a promoter derived from a heterologous source. The promoter can be a promoter inherent to the phoS gene or a promoter of other genes. In the bacteria of the present invention, the mutant phoS gene can be present on a vector that autonomously proliferates outside the chromosome, such as a plasmid, or can be integrated into the chromosome. The bacteria of the present invention can have only one copy of the mutant phoS gene, or two or more copies. The bacteria of the present invention can have only one mutant phoS gene, or two or more mutant phoS genes. The introduction of the mutant phoS gene, for example, as described below, can be carried out in the same manner as the introduction of the gene in the method for increasing the expression of the gene and the introduction of the bbFGF expression cassette.

[0197] The bacterium of the present invention may or may not have a wild-type phoS gene, but preferably does not have it.

[0198] A coryneform bacterium that does not have a wild-type phoS gene can be obtained by disrupting the wild-type phoS gene on the chromosome. The disruption of the wild-type phoS gene can be performed by a known method. Specifically, for example, the wild-type phoS gene can be disrupted by partially or completely deleting the promoter region and / or coding region of the wild-type phoS gene.

[0199] Furthermore, by replacing the wild-type phoS gene on the chromosome with a mutant phoS gene, a coryneform bacterium modified to have a mutant phoS gene instead of a wild-type phoS gene can be obtained. Examples of methods for performing such gene replacement include a method called "Red-driven integration" (Datsenko, K. A, and Wanner, BL Proc. Natl. Acad. Sci. USA. 97: 6640-6645 (2000)), a method combining Red-driven integration with an excision mechanism derived from lambda phage (Cho, EH, Gumport, RI, Gardner, JFJ Bacteriol. 184: 5200-5203 (2002)) (see WO2005 / 010175), a method using a linear DNA, a method using a plasmid containing a temperature-sensitive replication origin, a method using a plasmid capable of conjugative transfer, a method using a suicide vector that does not retain a replication origin that functions in a host, and the like (U.S. Patent No. 6303383, Japanese Patent Application Laid-Open No. 05-007491).

[0200] The PhoS protein is conjugated with the PhoR protein as a response regulator and functions, that is, it causes a response to the lack of phosphate in the environment. Therefore, the bacterium of the present invention has a phoR gene in a manner that allows the mutant PhoS protein to function. The phoR gene is a gene encoding the PhoR protein as a response regulator of the PhoRS system. "Having a phoR gene" is also referred to as "having a PhoR protein." Generally, the PhoR protein originally possessed by the bacterium of the present invention is conjugated with the mutant PhoS protein and functions. On the other hand, in the bacterium of the present invention, an appropriate phoR gene can be introduced on the basis of the phoR gene originally possessed by the bacterium of the present invention, or instead. The introduced phoR gene is not particularly limited as long as it encodes a PhoR protein that is conjugated with the mutant PhoS protein and functions.

[0201] As the phoR gene, for example, the phoR gene of coryneform bacteria can be cited. As the phoR gene of coryneform bacteria, specifically, for example, the phoR gene of Corynebacterium glutamicum YDK010 strain, Corynebacterium glutamicum ATCC13032 strain, Corynebacterium glutamicum ATCC14067 strain, Corynebacterium sphaeroides, Corynebacterium sphaeroides and Corynebacterium efficacious can be cited. The base sequence of the phoR gene of Corynebacterium glutamicum ATCC13032 strain and the amino acid sequence of the PhoR protein are represented by SEQ ID NO.8 and 9, respectively.

[0202] As long as the phoR gene maintains its original function, it may be a variant of the phoR gene as described above. Similarly, as long as the PhoR protein maintains its original function, it may be a variant of the PhoR protein as described above. That is, the term "phoR gene" refers to the phoR gene as described above and its conservative variants. Similarly, the term "PhoR protein" refers to the PhoR protein as described above and its conservative variants. Regarding the variants of the PhoR protein and the phoR gene, the description of the conservative variants of the bbFGF gene and bbFGF can be applied. For example, as long as the phoR gene maintains its original function, it may be a gene encoding a protein having an amino acid sequence in which one or more amino acids are substituted, deleted, inserted and / or added at one or more positions in the amino acid sequence. In addition, for example, as long as the phoR gene maintains its original function, it may be a gene encoding a protein having an amino acid sequence having an identity of 80% or more, preferably 90% or more, more preferably 95% or more, further preferably 97% or more, and particularly preferably 99% or more relative to the entire amino acid sequence. It should be noted that the so-called "maintaining the original function" may mean that the variant of the protein has the function of being a PhoR protein (for example, the function of the protein containing the amino acid sequence represented by SEQ ID NO.9) in the PhoR protein. In addition, the so-called "maintaining the original function" may mean that the variant of the protein has the function of being a response regulator of the PhoRS system in the PhoR protein. That is, the so-called "function as a PhoR protein" may specifically mean having the function of being a response regulator of the PhoRS system. The so-called "function as a response regulator of the PhoRS system" may specifically mean the function of conjugating with the PhoS protein as a sensor kinase and causing a response to the lack of phosphate in the environment. The so-called "function as a response regulator of the PhoRS system" may more specifically mean the function of being activated by sensing the lack of phosphate in the environment and transferring the phosphate group from the self-phosphorylated PhoS protein, and controlling the expression of genes that respond to the lack of phosphate in the environment.

[0203] Whether the variant of the PhoR protein has the function of a response regulator of the PhoRS system can be confirmed, for example, by introducing a gene encoding the variant into a phoR gene-deficient strain of a coryneform bacterium and confirming whether the responsiveness to phosphate deficiency is complemented. Complementation of the responsiveness to phosphate deficiency can be detected, for example, as an increase in growth and proliferation under phosphate deficiency conditions, or as an induction of expression of a gene known to be induced to be expressed under phosphate deficiency conditions (J. Bacteriol., 188, 724-732 (2006)). As a phoR gene-deficient strain of a coryneform bacterium, for example, a phoR gene-deficient strain of Corynebacterium glutamicum YDK010 strain and a phoR gene-deficient strain of Corynebacterium glutamicum ATCC13032 strain can be used.

[0204] (1-3-2) Decreased activity of cell surface proteins

[0205] The activity of the cell surface protein of the bacterium of the present invention may be reduced. Specifically, the activity of the cell surface protein of the bacterium of the present invention may be reduced compared to the unmodified strain. The so-called "reduced activity of the cell surface protein" may particularly mean that the number of molecules per unit cell of the cell surface protein is reduced. In the following, the cell surface protein and the gene encoding it are described.

[0206] Cell surface protein is the protein that constitutes the cell surface layer (S layer) of bacteria and archaea. As the cell surface protein of rod-shaped bacteria, PS1, PS2 (CspB), SlpA (CspA) can be mentioned. As the cell surface protein of rod-shaped bacteria, specifically, PS1 and PS2 (CspB) of Corynebacterium glutamicum (Japanese Patent Table Hei 6-502548) and SlpA (CspA) of Corynebacterium stagnans (Japanese Patent Laid-Open Hei 10-108675) can be mentioned. Among them, it is preferably a cell surface protein that reduces the activity of PS2 protein.

[0207] The base sequence of the cspB gene of Corynebacterium glutamicum ATCC13869 and the amino acid sequence of the PS2 protein (CspB protein) encoded by the gene are represented by SEQ ID NOs. 10 and 11, respectively.

[0208] In addition, for example, about 28 strains of Corynebacterium glutamicum, the amino acid sequence of CspB homologs was reported (J Biotechnol., 112, 177-193 (2004)). The accession numbers (GenBank accession numbers) of the genome database of the NCBI database of these 28 strains of Corynebacterium glutamicum and cspB gene homologs are shown below as examples (the accession numbers of the genome database are shown in brackets).

[0209] Corynebacterium glutamicum ATCC13058 (AY524990)

[0210] Corynebacterium glutamicum ATCC13744 (AY524991)

[0211] Corynebacterium glutamicum ATCC13745 (AY524992)

[0212] Corynebacterium glutamicum ATCC14017 (AY524993)

[0213] Corynebacterium glutamicum ATCC14020 (AY525009)

[0214] Corynebacterium glutamicum ATCC14067 (AY524994)

[0215] Corynebacterium glutamicum ATCC14068 (AY525010)

[0216] Corynebacterium glutamicum ATCC14747 (AY525011)

[0217] Corynebacterium glutamicum ATCC14751(AY524995)

[0218] Corynebacterium glutamicum ATCC14752 (AY524996)

[0219] Corynebacterium glutamicum ATCC14915 (AY524997)

[0220] Corynebacterium glutamicum ATCC15243 (AY524998)

[0221] Corynebacterium glutamicum ATCC15354 (AY524999)

[0222] Corynebacterium glutamicum ATCC17965 (AY525000)

[0223] Corynebacterium glutamicum ATCC17966 (AY525001)

[0224] Corynebacterium glutamicum ATCC19223 (AY525002)

[0225] Corynebacterium glutamicum ATCC19240 (AY525012)

[0226] Corynebacterium glutamicum ATCC21341(AY525003)

[0227] Corynebacterium glutamicum ATCC21645 (AY525004)

[0228] Corynebacterium glutamicum ATCC31808 (AY525013)

[0229] Corynebacterium glutamicum ATCC31830 (AY525007)

[0230] Corynebacterium glutamicum ATCC31832 (AY525008)

[0231] Corynebacterium glutamicum LP-6 (AY525014)

[0232] Corynebacterium glutamicum DSM20137 (AY525015)

[0233] Corynebacterium glutamicum DSM20598 (AY525016)

[0234] Corynebacterium glutamicum DSM46307 (AY525017)

[0235] Corynebacterium glutamicum 22220 (AY525005)

[0236] Corynebacterium glutamicum 22243 (AY525006)

[0237] Depending on the species or strain to which the rod-shaped bacteria belong, there are differences in the base sequence of the gene encoding the cell surface protein. Therefore, as long as the gene encoding the cell surface protein maintains the original function, it can be a variant of the gene encoding the cell surface protein as described above. Similarly, as long as the cell surface protein maintains the original function, it can be a variant of the cell surface protein as described above. That is, for example, the term "cspB gene" refers to the cspB gene as described above and its conservative variants. Similarly, the term "CspB protein" refers to the CspB protein as described above and its conservative variants. Regarding variants of cell surface proteins and genes encoding them, the records involving the conservative variants of the bbFGF gene and bbFGF can be applied. For example, as long as the gene encoding the cell surface protein maintains the original function, it can be a gene encoding a protein having an amino acid sequence in which one or more amino acids are substituted, deleted, inserted and / or added at one or more positions in the amino acid sequence. Furthermore, for example, a gene encoding a cell surface protein may be a gene encoding a protein having an amino acid sequence having 80% or more, preferably 90% or more, more preferably 95% or more, further preferably 97% or more, and particularly preferably 99% or more identity to the entire amino acid sequence, as long as the original function is maintained. It should be noted that "maintaining the original function" may be, for example, a property of increasing the secretory production of a heterologous protein such as bbFGF when the activity is reduced in coryneform bacteria compared to an unmodified strain.

[0238] The term “having a property of increasing the secretory production of a heterologous protein compared to an unmodified strain when the activity is reduced in a coryneform bacterium” means a property of giving the coryneform bacterium the ability to secrete and produce a larger amount of a heterologous protein than an unmodified strain when the activity is reduced in a coryneform bacterium. The so-called “unmodified strain” refers to a control strain in which the activity of a cell surface protein is not reduced, for example, it may be a wild-type strain or a parent strain. The term “secretory production of a heterologous protein in a larger amount compared to an unmodified strain” means that there is no particular limitation as long as the secretory production of a heterologous protein is increased compared to an unmodified strain. For example, the amount of heterologous protein that can be secreted and produced as the accumulation in the culture medium and / or on the bacterial surface is preferably 1.1 times or more, more preferably 1.2 times or more, further preferably 1.3 times or more, and particularly preferably 2 times or more of that of an unmodified strain. In addition, the so-called "secretion and production of a larger amount of heterologous protein than that of an unmodified strain" may mean that the heterologous protein cannot be detected when the culture supernatant of an unmodified strain without concentration is subjected to SDS-PAGE and stained with CBB, while the heterologous protein can be detected when the culture supernatant of a modified strain without concentration is subjected to SDS-PAGE and stained with CBB.

[0239] Whether or not a certain protein has the property of increasing the secretory production of a heterologous protein such as bbFGF when its activity is reduced in a coryneform bacterium compared to an unmodified strain can be confirmed by preparing a strain that is modified based on a strain belonging to a coryneform bacterium in such a manner that the activity of the protein is reduced, quantifying the amount of the heterologous protein secreted and produced when the modified strain is cultured in a medium, and comparing the amount of the heterologous protein secreted and produced when the strain before modification (unmodified strain) is cultured in a medium.

[0240] The term "the activity of the cell surface protein is reduced" includes the case where the coryneform bacteria are modified in such a way that the activity of the cell surface protein is reduced, and the case where the activity of the cell surface protein is already reduced in the coryneform bacteria. The term "the case where the activity of the cell surface protein is already reduced in the coryneform bacteria" includes the case where the coryneform bacteria does not originally have the cell surface protein. That is, as coryneform bacteria with reduced cell surface protein activity, for example, coryneform bacteria that do not originally have the cell surface protein can be cited. As "the case where the coryneform bacteria do not originally have the cell surface protein", for example, the case where the coryneform bacteria do not originally have the gene encoding the cell surface protein can be cited. It should be noted that the so-called "coryneform bacteria do not originally have the cell surface protein" may be that the coryneform bacteria do not originally have one or more proteins selected from the cell surface proteins found in other strains of the species to which the coryneform bacteria belongs. For example, "Corynebacterium glutamicum does not originally have a cell surface protein" means that the Corynebacterium glutamicum strain does not originally have one or more proteins selected from cell surface proteins found in other Corynebacterium glutamicum strains, i.e., for example, PS1 and / or PS2 (CspB). Examples of coryneform bacteria that do not originally have a cell surface protein include Corynebacterium glutamicum ATCC13032 that does not originally have a cspB gene.

[0241] (1-3-3) Protein secretion system

[0242] The bacterium of the present invention has a protein secretion system. The bacterium of the present invention may originally have a protein secretion system. The protein secretion system is not particularly limited as long as it can secrete proteins such as bbFGF. As the protein secretion system, the Sec system (Sec system secretion apparatus) and the Tat system (Tat system secretion apparatus) can be mentioned. The bacterium of the present invention can be modified in a manner that increases the activity of the protein secretion system (for example, the Tat system secretion apparatus). The bacterium of the present invention, specifically, can be modified in a manner that increases the activity of the protein secretion system (for example, the Tat system secretion apparatus) compared to the unmodified strain. With regard to the activity of the Tat system secretion apparatus, for example, it can be increased by increasing the expression of one or more genes selected from the genes encoding the Tat system secretion apparatus. That is, the bacterium of the present invention, more specifically, can be modified in a manner that increases the expression of one or more genes selected from the genes encoding the Tat system secretion apparatus. The increase in the activity of the Tat system secretion apparatus is particularly suitable for the case where bbFGF is secreted and produced using a signal peptide that depends on the Tat system. A method for increasing the expression of a gene encoding the secretion machinery of the Tat system is described in Japanese Patent No. 4730302.

[0243] Examples of the gene encoding the secretion machinery of the Tat system include the tatA gene, the tatB gene, the tatC gene, and the tatE gene.

[0244] Specific examples of genes encoding the secretion machinery of the Tat system include the tatA gene, tatB gene, and tatC gene of Corynebacterium glutamicum. The tatA gene, tatB gene, and tatC gene of Corynebacterium glutamicum ATCC 13032 correspond to the complementary sequence of the sequence at positions 1571065 to 1571382, the complementary sequence of the sequence at positions 1167110 to 1167580, and the complementary sequence of the sequence at positions 1569929 to 1570873, respectively, in the genome sequence registered as GenBank accession NC_003450 (VERSION NC_003450.3GI:58036263) in the NCBI database. In addition, the TatA protein, TatB protein, and TatC protein of Corynebacterium glutamicum ATCC 13032 are registered as GenBank accession NP_600707 (version NP_600707.1 GI:19552705, locus_tag="NCgl1434"), GenBank accession NP_600350 (version NP_600350.1 GI:19552348, locus_tag="NCgl1077"), and GenBank accession NP_600706 (version NP_600706.1 GI:19552704, locus_tag="NCgl1433"), respectively. The base sequences of the tatA gene, tatB gene, and tatC gene of Corynebacterium glutamicum ATCC 13032, and the amino acid sequences of the TatA protein, TatB protein, and TatC protein are represented by SEQ ID NOs. 12 to 17.

[0245] In addition, as genes encoding the secretion machinery of the Tat system, specifically, there can be mentioned the tatA gene, tatB gene, tatC gene, and tatE gene of Escherichia coli. The tatA gene, tatB gene, tatC gene, and tatE gene of Escherichia coli K-12 MG1655 correspond to the sequence at positions 4019968 to 4020237, the sequence at positions 4020241 to 4020756, the sequence at positions 4020759 to 4021535, and the sequence at positions 658170 to 658373, respectively, in the genome sequence registered as GenBank accession NC_000913 (VERSION NC_000913.2 GI:49175990) in the NCBI database. In addition, the TatA protein, TatB protein, TatC protein, and TatE protein of Escherichia coli K-12 MG1655 were accessioned as GenBank accession NP_418280 (version NP_418280.4 GI:90111653, locus_tag="b3836"), GenBank accession YP_026270 (version YP_026270.1 GI:49176428, locus_tag="b3838"), GenBank accession NP_418282 (version NP_418282.1 GI:16131687, locus_tag="b3839"), and GenBank accession NP_415160 (version NP_415160.1 GI:16128610, locus_tag="b0627") logged in.

[0246] The gene encoding the Tat system secretion apparatus may be a variant of the gene encoding the Tat system secretion apparatus as described above, as long as it maintains its original function. Similarly, the Tat system secretion apparatus may be a variant of the Tat system secretion apparatus as described above, as long as it maintains its original function. That is, for example, the terms "tatA gene", "tatB gene", "tatC gene" and "tatE gene" include conservative variants thereof in addition to the tatA gene, tatB gene, tatC gene and tatE gene as described above, respectively. Similarly, the terms "TatA protein", "TatB protein", "TatC protein" and "TatE protein" include conservative variants thereof in addition to the TatA protein, TatB protein, TatC protein and TatE protein as described above, respectively. With respect to variants of the Tat system secretion apparatus and the gene encoding it, the descriptions concerning the conservative variants of the bbFGF gene and bbFGF can be applied. For example, as long as the original function is maintained, the gene encoding the Tat system secretion apparatus may be a gene encoding a protein having an amino acid sequence in which one or more amino acids are substituted, deleted, inserted and / or added at one or more positions in the amino acid sequence. In addition, for example, as long as the original function is maintained, the gene encoding the Tat system secretion apparatus may be a gene encoding a protein having an amino acid sequence having an identity of 80% or more, preferably 90% or more, more preferably 95% or more, further preferably 97% or more, and particularly preferably 99% or more to the entire amino acid sequence. It should be noted that the so-called "maintaining the original function" for the Tat system secretion apparatus may be a function of secreting a protein to which a Tat system-dependent signal peptide is added to the N-terminus to the outside of the cell.

[0247] The increase in the activity of the Tat system secretion apparatus can be confirmed, for example, by confirming that the secretory production of a protein to which a Tat system-dependent signal peptide is added at the N-terminus is increased. The secretory production of a protein to which a Tat system-dependent signal peptide is added at the N-terminus can be increased, for example, by 1.5 times or more, 2 times or more, or 3 times or more of that of an unmodified strain.

[0248] (1-3-4) Decreased activity of PMT

[0249] The bacterium of the present invention may be a bacterium in which the activity of protein O-mannosyltransferase (PMT) is reduced. Specifically, the bacterium of the present invention may be a bacterium in which the activity of PMT is reduced compared to an unmodified strain. "The activity of PMT is reduced" may mean, in particular, that the number of molecules per unit cell of PMT is reduced. Hereinafter, PMT and a gene encoding PMT will be described.

[0250] "Protein O-mannosyltransferase (PMT)" may refer to a protein having an activity of catalyzing a reaction in which a secretory protein undergoes O-mannosylation. This activity is also referred to as "PMT activity." A gene encoding PMT is also referred to as a "PMT gene."

[0251] The base sequence of the PMT gene of coryneform bacteria and the amino acid sequence of PMT can be obtained from technical documents such as public databases such as NCBI, patent documents, etc. The base sequence of the PMT gene (also referred to as "pmt1 gene") of Corynebacterium glutamicum ATCC 13869 strain and the amino acid sequence of the PMT encoded by the gene (also referred to as "PMT1") are shown in SEQ ID NOs. 39 and 40, respectively.

[0252] Sometimes, there are differences in the base sequence of the PMT gene depending on the species or strain to which the coryneform bacteria belong, so as long as the PMT gene maintains its original function, it can be a variant of the PMT gene as described above. Similarly, as long as PMT maintains its original function, it can be a variant of PMT as described above. That is, the term "PMT gene" includes not only the PMT gene as described above, but also its conservative variants. Similarly, the term "PMT" includes not only the PMT as described above, but also its conservative variants. For variants of PMT and genes encoding PMT, the records involving the bbFGF gene and conservative variants of bbFGF can be applied. For example, as long as the PMT gene maintains its original function, it can be a gene encoding a protein having an amino acid sequence in which one or more amino acids are substituted, deleted, inserted and / or added at one or more positions in the amino acid sequence. In addition, for example, the PMT gene may be a gene encoding a protein having an amino acid sequence that is 80% or more, preferably 90% or more, more preferably 95% or more, further preferably 97% or more, and particularly preferably 99% or more identical to the entire amino acid sequence, as long as the original function is maintained. It should be noted that "maintaining the original function" may be, for example, having PMT activity in PMT.

[0253] Whether a protein has PMT activity can be confirmed, for example, by preparing a strain belonging to a coryneform bacterium in a manner that reduces the activity of the protein, and confirming that the degree of O-glycosylated modification of the protein secreted and produced when the modified strain is cultured in a medium is reduced compared to the degree of O-glycosylated modification of the protein secreted and produced when the strain before modification (unmodified strain) is cultured in a medium.

[0254] (1-4) Methods for increasing protein activity

[0255] Hereinafter, methods for increasing protein activity (including methods for increasing gene expression) will be described.

[0256] The so-called "increase in the activity of protein" means that the activity of the protein increases compared with the unmodified strain. The so-called "increase in the activity of protein" specifically means that the activity of the unit cell of the protein increases relative to the unmodified strain. The so-called "unmodified strain" here means a control strain that is not modified in a manner that reduces the activity of the target protein. As an unmodified strain, a wild-type strain and a parent strain can be cited. As an unmodified strain, specifically, a standard strain (type strain) of each bacterial species can be cited. In addition, as an unmodified strain, specifically, the strains exemplified in the description of rod-shaped bacteria can be cited. That is, in one embodiment, the activity of the protein can be increased compared with the standard strain (i.e., the standard strain of the species to which the bacterium of the present invention belongs). In addition, in another embodiment, the activity of the protein can be increased compared with Corynebacterium glutamicum ATCC13869 strain. In addition, in another embodiment, the activity of the protein can be increased compared with Corynebacterium glutamicum ATCC 13032 strain. In addition, in another way, the activity of the protein can be increased compared with Corynebacterium glutamicum AJ12036 (FERMBP-734). In addition, in another way, the activity of the protein can be increased compared with Corynebacterium glutamicum YDK010 strain. It should be noted that "the activity of the protein increases" is also referred to as "the activity of the protein is enhanced". The so-called "the activity of the protein increases", more specifically, means that compared with the unmodified strain, the number of molecules per unit cell of the protein increases and / or the functional enhancement of the unit molecule of the protein. The so-called "activity" in the case of the so-called "the activity of the protein increases", is not limited to the catalytic activity of the protein, and can mean the transcription amount (mRNA amount) or the translation amount (amount of the protein) of the gene encoding the protein. The so-called "number of molecules per unit cell of the protein", can mean the average value of the unit cell of the number of molecules of the protein. In addition, the so-called "the activity of the protein increases", not only includes increasing the activity of the protein in the strain originally having the activity of the target protein, but also includes giving the activity of the protein to the strain without the activity of the target protein. Furthermore, as a result, as long as the activity of the protein is increased, it is possible to impart an appropriate target protein activity even if the activity of the target protein originally possessed by the host has been reduced or eliminated.

[0257] The degree of increase in the activity of the protein is not particularly limited as long as the activity of the protein is increased compared to the unmodified strain. The activity of the protein can be increased, for example, by 1.5 times or more, 2 times or more, or 3 times or more of the unmodified strain. In addition, when the unmodified strain does not have the activity of the target protein, the protein can be produced by introducing a gene encoding the protein, for example, the protein can be produced to the extent that its activity can be measured.

[0258] The modification of increasing the activity of a protein, for example, can be achieved by increasing the expression of the gene encoding the protein. The so-called "increasing the expression of a gene" means that the expression of the gene is increased compared with unmodified strains such as wild-type strains and parent strains. The so-called "increasing the expression of a gene" specifically means that the expression amount per unit cell of the gene is increased compared with the unmodified strain. The so-called "expression amount per unit cell of a gene" can mean the average value of the expression amount per unit cell of the gene. The so-called "increasing the expression of a gene" more specifically can mean that the transcription amount (mRNA amount) of the gene is increased and / or the translation amount (protein amount) of the gene is increased. It should be noted that "increasing the expression of a gene" is also referred to as "enhanced expression of a gene". The expression of a gene, for example, can be increased to more than 1.5 times, more than 2 times or more than 3 times that of an unmodified strain. In addition, with respect to "increasing the expression of a gene", it is not only included in the strain that originally expresses the target gene to increase the expression amount of the gene, but also included in the expression of the gene in the strain that originally does not express the target gene. That is, "increasing the expression of a gene" may mean, for example, introducing the gene into a strain that does not have the target gene and expressing the gene.

[0259] Increased gene expression can be achieved, for example, by increasing the copy number of the gene.

[0260] The increase of the copy number of a gene can be achieved by introducing the gene into the chromosome of the host. For example, homologous recombination can be used to carry out (Miller, JH Experiments in Molecular Genetics, 1972, Cold Spring Harbor Laboratory). As a gene introduction method using homologous recombination, for example, Red-mediated gene recombination (Red-driven integration) method (Datsenko, KA, and Wanner, BL Proc. Natl. Acad. Sci. USA. 97: 6640-6645 (2000)) and other methods using linear DNA, methods using plasmids comprising temperature sensitivity replication origins, methods using plasmids that can be conjugated and transferred, methods using suicide vectors that do not remain in the replication origin that functions in the host, and transduction (transduction) methods using bacteriophages. Specifically, the host can be transformed with a recombinant DNA comprising a target gene, and homologous recombination occurs with the target site on the chromosome of the host, thus importing the gene on the chromosome of the host. The structure of the recombinant DNA used in homologous recombination is not particularly limited if homologous recombination occurs in a desired manner. For example, a linear DNA containing a target gene, i.e., a linear DNA having the same base sequence as the upstream and downstream of the target site on the chromosome at both ends of the gene, can be used to transform the host, and homologous recombination occurs in the upstream and downstream of the target site, respectively, thereby replacing the target site with the gene. The recombinant DNA used for homologous recombination can be provided with a marker gene for selecting a transformant. The gene can be introduced into only one copy, or two or more copies can be introduced. For example, homologous recombination can be performed by targeting a base sequence having multiple copies on the chromosome, and multiple copies of the gene can be introduced into the chromosome. As a sequence having multiple copies on the chromosome, a repetitive DNA sequence (repetitive DNA) and an inverted repeat (inverted repeat) present at both ends of a transposon can be cited. In addition, appropriate sequences on chromosomes such as genes not required for the production of the target product can be used as targets for homologous recombination. In addition, genes can be randomly introduced into chromosomes using transposons or Mini-Mu (Japanese Patent Publication No. 2-109985, US5,882,888, EP805867B1). It should be noted that the method of modifying chromosomes using such homologous recombination is not limited to the introduction of target genes, and can be used for any modification of chromosomes such as modification of expression regulatory sequences.

[0261] Confirmation of the introduction of the target gene into the chromosome can be carried out by Southern blot hybridization using a probe having a sequence complementary to all or part of the gene, or PCR using primers prepared based on the sequence of the gene.

[0262] In addition, the increase in the number of copies of a gene can also be achieved by introducing a vector containing the gene into the host. For example, an expression vector of the gene can be constructed by connecting a DNA fragment containing the target gene to a vector that functions in the host, and the host is transformed by the expression vector, thereby increasing the number of copies of the gene. The DNA fragment containing the target gene can, for example, be obtained by PCR using the genomic DNA of a microorganism with the target gene as a template. As a vector, a vector that can replicate autonomously in the host's cell can be used. The vector is preferably a multicopy vector. In addition, in order to select transformants, the vector preferably has markers such as antibiotic resistance genes. In addition, the vector can be equipped with a promoter and a terminator for expressing the inserted gene. The vector can be, for example, a vector derived from a bacterial plasmid, a vector derived from a yeast plasmid, a vector derived from a phage, a clay or a phagemid, etc. Specific examples of vectors capable of autonomous replication in coryneform bacteria include pHM1519 (Agric. Biol. Chem., 48, 2901-2903 (1984)); pAM330 (Agric. Biol. Chem., 48, 2901-2903 (1984)); 2901-2903 (1984)); these improved plasmids with drug resistance genes; pCRY30 (Japanese Patent Laid-Open No. 3-210184); pCRY21, pCRY2KE, pCRY2KX, pCRY31, pCRY3KE and pCRY3KX (Japanese Patent Laid-Open No. 2-72876, U.S. Patent No. 5,185,262); pCRY2 and pCRY3 (Japanese Patent Laid-Open No. 1-191686); pAJ655, pAJ611 and pAJ1844 (Japanese Patent Laid-Open No. 58-1929 00); pCG1 (Japanese Patent Application Laid-Open No. 57-134500); pCG2 (Japanese Patent Application Laid-Open No. 58-35197); pCG4 and pCG11 (Japanese Patent Application Laid-Open No. 57-183799); pVK7 (Japanese Patent Application Laid-Open No. 10-215883); pVK9 (US2006-0141588); pVC7 (Japanese Patent Application Laid-Open No. 9-070291); pVS7 (WO2013 / 069634); pPK4 (Japanese Patent Application Laid-Open No. 9-322774); pPK5 (WO2018 / 074579).In addition, as a vector capable of autonomous replication in coryneform bacteria, specifically, for example, variants of pVC7 can be cited: pVC7N (Shuhei Hashiro et al., High copy number mutants derived from Corynebacterium glutamicum cryptic plasmid pAM330 and copynumber control, J Biosci Bioeng, 2019 May; 127 (5): 529-538.), pVC7H1, pVC7H2, pVC7H3, pVC7H4, pVC7H5, pVC7H6, pVC7H7 (WO2018 / 179834). In addition, as a vector capable of autonomous replication in coryneform bacteria, specifically, for example, variants of pPK4 can be cited: pPK4H1, pPK4H2, pPK4H3, pPK4H4, pPK4H5, pPK4H6 (WO2018 / 179834). As vectors, in particular, pVC series vectors and pPK series vectors can be cited. As pVC series vectors, pVC7 and its variants, vectors whose antibiotic resistance gene is replaced by another antibiotic resistance gene, and vectors having a base sequence identity of 90% or more, 95% or more, 97% or more, or 99% or more with the vectors can be cited. As pPK series vectors, pPK4, pPK5 and their variants, vectors whose antibiotic resistance gene is replaced by another antibiotic resistance gene, and vectors having a base sequence identity of 90% or more, 95% or more, 97% or more, or 99% or more with the vectors can be cited. As vectors, pVC7, pVC7N, pPK4, and pPK5 can be further cited in particular.

[0263] When introducing a gene, the gene can be expressed in the host. Specifically, the gene can be expressed in a controlled manner by a promoter that functions in the host. The promoter is not particularly limited if it functions in the host. The so-called "promoter that functions in the host" refers to a promoter that has promoter activity in the host. The promoter can be a promoter derived from the host or a promoter from a heterologous source. The promoter can be an inherent promoter of the introduced gene or a promoter of other genes. In addition, the promoter can be inducible or constitutive for the expression of the gene.

[0264] Examples of promoters that can be used in coryneform bacteria include promoters of genes involved in glycolysis, pentose phosphate pathway, TCA circuit, amino acid biosynthesis, and cell surface proteins. As the promoter of amino acid biosynthesis gene, specifically, for example, glutamate dehydrogenase gene of glutamate biosynthesis system, glutamine synthetase gene of glutamine synthesis system, aspartate kinase gene of lysine biosynthesis system, homoserine dehydrogenase gene of threonine biosynthesis system, acetohydroxy acid synthetase gene of isoleucine and valine biosynthesis system, 2-isopropylmalate synthase gene of leucine biosynthesis system, glutamate kinase gene of proline and arginine biosynthesis system, phosphoribosyl-ATP pyrophosphokinase gene of histidine biosynthesis system, deoxyarabinoheptulose phosphate (DAHP) synthase gene of aromatic amino acid biosynthesis system such as tryptophan, tyrosine and phenylalanine, phosphoribosyl pyrophosphate (PRPP) amidotransferase gene in nucleic acid biosynthesis system such as inosinic acid and guanylic acid, inosinic acid dehydrogenase gene and guanylate synthetase gene promoter. In addition, as the promoter that can be used in coryneform bacteria, the strong promoter as described below can be enumerated.

[0265] Downstream of the gene, a terminator for transcription termination can be configured. The terminator is not particularly limited if it functions in the host. The terminator can be a terminator of host origin or a terminator of heterologous origin. The terminator can be a terminator inherent to the introduced gene or a terminator of other genes. As a terminator, specifically, for example, the terminator of bacteriophage BFK20 can be cited.

[0266] Vectors, promoters, and terminators that can be used in various microorganisms are described in detail in, for example, "Basic Course in Microbiology 8: Genetic Engineering, Kyoritsu Publishing, 1987," and can be used.

[0267] In addition, when two or more genes are introduced, each gene can be maintained in the host and can be expressed. For example, two or more genes can all be maintained on a single expression vector, or all can be maintained on chromosomes. In addition, two or more genes can be maintained on multiple expression vectors respectively, or can be maintained on a single or multiple expression vectors and chromosomes respectively. In addition, an operon can be formed by two or more genes to be introduced.

[0268] The gene to be introduced is not particularly limited if it encodes a protein that functions in the host. The gene to be introduced may be a gene of host origin or a gene of heterologous origin. The gene to be introduced, for example, can be obtained by PCR using primers designed based on the base sequence of the gene, using the genomic DNA of an organism having the gene, a plasmid carrying the gene, etc. as a template. In addition, the gene to be introduced, for example, can be fully synthesized based on the base sequence of the gene (Gene, 60 (1), 115-127 (1987)). The obtained gene can be used as is or with appropriate modification. That is, its variant can be obtained by modifying the gene. The modification of the gene can be carried out by a known method. For example, by a site-specific mutagenesis method, a target mutation can be introduced into a target site of DNA. That is, for example, by a site-specific mutagenesis method, the coding region of the gene can be modified in a manner such that the encoded protein contains substitution, deletion, insertion and / or addition of amino acid residues in a determined site. As site-specific mutagenesis methods, there are methods using PCR (Higuchi, R., 61, in PCR technology, Erlich, HA Eds., Stockton press (1989); Carter, P., Meth. in Enzymol., 154, 382 (1987)), methods using phage (Kramer, W. and Frits, HJ, Meth. in Enzymol., 154, 350 (1987); Kunkel, TA et al., Meth. in Enzymol., 154, 367 (1987)). Alternatively, fully synthesized gene variants are also possible.

[0269] It should be noted that, in the case where a protein functions as a complex composed of multiple subunits, as long as the activity of the protein is increased as a result, all of these multiple subunits may be modified, or only a part of them may be modified. That is, for example, in the case where the activity of a protein is increased by increasing the expression of a gene, the expression of all of the multiple genes encoding its subunits may be enhanced, or the expression of only a part of them may be enhanced. Generally, it is preferred to enhance the expression of all of the multiple genes encoding its subunits. In addition, as long as each subunit constituting the complex has the function of the target protein, it may be of one biological origin or of two or more different biological origins. That is, for example, genes of the same biological origin encoding multiple subunits may be introduced into the host, or genes of different biological origins encoding multiple subunits may be introduced into the host.

[0270] In addition, the increase in gene expression can be achieved by improving the transcription efficiency of the gene. In addition, the increase in gene expression can be achieved by improving the translation efficiency of the gene. With regard to the improvement of the transcription efficiency and translation efficiency of the gene, for example, it can be achieved by modifying the expression regulatory sequence. The so-called "expression regulatory sequence" is a general term for the position that affects the expression of the gene. As an expression regulatory sequence, for example, a promoter, a Shine-Dalgarno (SD) sequence (also referred to as a ribosome binding site (RBS)) and the spacer region between the RBS and the start codon can be cited. The expression regulatory sequence can be determined using gene analysis software such as promoter retrieval vectors and GENETYX. The modification of these expression regulatory sequences, for example, can be carried out by using a method using a temperature-sensitive vector, a Red-mediated gene recombination method (WO2005 / 010175).

[0271] The improvement of gene transcription efficiency can be achieved, for example, by replacing the promoter of the gene on the chromosome with a more potent promoter. The so-called "strong promoter" means a promoter that increases gene transcription compared to the original wild-type promoter. As a more powerful promoter that can be used in coryneform bacteria, for example, there can be mentioned the artificially designed modified P54-6 promoter (Appl. Microbiol. Biotechnol., 53, 674-679 (2000)), the pta, aceA, aceB, adh, amyE promoters that can be induced by acetic acid, ethanol, pyruvic acid, etc., the cspB, SOD, tuf (EF-Tu) promoter (Journal of Biotechnology 104 (2003) 311-323, Appl Environ Microbiol. 2005 Dec; 71 (12): 8587-96.), lac promoter, tac promoter, trc promoter, F1 promoter, T7 promoter, T5 promoter, T3 promoter, SP6 promoter. In addition, as a more powerful promoter, a highly active promoter of an existing promoter can be obtained by using various reporter genes. For example, the activity of the promoter can be improved by bringing the -35 and -10 regions in the promoter region close to the consensus sequence (International Publication No. 00 / 18935). As highly active promoters, various tac promoters can be cited (Katashkina JI et al. Russian Federation Patent application 2006134574). The evaluation method of the intensity of the promoter and the example of the powerful promoter are recorded in the paper (Prokaryotic promoters in biotechnology. Biotechnol. Annu. Rev., 1, 105-128 (1995)) of Goldstein et al.

[0272] The improvement of the translation efficiency of a gene can be achieved, for example, by replacing the Shine-Dalgarno (SD) sequence (also called ribosome binding site (RBS)) of the gene on the chromosome with a more powerful SD sequence. The so-called "more powerful SD sequence" means an SD sequence whose translation of mRNA is improved compared to the wild-type SD sequence that originally existed. As a more powerful SD sequence, for example, the RBS of gene 10 derived from bacteriophage T7 can be cited (Olins PO et al, Gene, 1988, 73, 227-235). Furthermore, it is known that the replacement or insertion or deletion of multiple nucleotides in the spacer region between the RBS and the start codon, especially the sequence upstream of the start codon (5'-UTR), has a great influence on the stability and translation efficiency of mRNA, and the translation efficiency of the gene can also be improved by modifying them.

[0273] The improvement of the translation efficiency of a gene can also be achieved, for example, by modifying codons. For example, the translation efficiency of a gene can be improved by replacing rare codons present in the gene with synonymous codons that are used at a higher frequency. That is, the gene to be introduced can be modified, for example, in a manner that has the most suitable codons according to the codon usage frequency of the host used. The replacement of codons can be carried out, for example, by site-specific mutagenesis. In addition, the gene fragment after codon replacement can be fully synthesized. The usage frequency of codons in various organisms is disclosed in the "Codon Usage Database" (http: / / www.kazusa.or.jp / codon; Nakamura, Y. et al, Nucl.Acids Res., 28, 292 (2000)).

[0274] Furthermore, the increase in gene expression can also be achieved by amplifying a regulator gene that increases gene expression, or by deleting or weakening a regulator gene that decreases gene expression.

[0275] The above-mentioned methods for increasing gene expression may be used alone or in any combination.

[0276] In addition, modifications that increase the activity of a protein can also be achieved, for example, by enhancing the specific activity of the protein. Proteins with enhanced specific activity can be obtained, for example, by exploring various organisms. In addition, highly active proteins can be obtained by introducing mutations into existing proteins. The introduced mutations can, for example, be deletions, insertions, and / or additions of one or more amino acids at one or more positions of the protein. The introduction of mutations can, for example, be carried out by site-specific mutation methods as described above. In addition, the introduction of mutations can also be carried out, for example, by mutation treatment. As mutation treatments, X-ray irradiation, ultraviolet irradiation, and treatments based on mutagens such as N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), ethyl methanesulfonate (EMS), and methyl methanesulfonate (MMS) can be cited. In addition, DNA can be directly treated with hydroxylamine in vitro to induce random mutations. The enhancement of specific activity can be used alone or in combination with the method for enhancing gene expression as described above.

[0277] The method of transformation is not particularly limited, and conventionally known methods can be used. For example, a method of increasing the permeability of DNA by treating the recipient bacterial cells with calcium chloride as reported for Escherichia coli K-12 (Mandel, M. and Higa, A., J. Mol. Biol. 1970, 53, 159-162) or a method of preparing competent cells from cells in the proliferation stage and introducing DNA as reported for Bacillus subtilis (Duncan, CH, Wilson, GA and Young, FE., 1977. Gene 1: 153-167). Alternatively, a method known for Bacillus subtilis, actinomycetes and yeast, in which the cells of DNA receiving bacteria are made into a protoplast or spheroplast state that is easy to take up recombinant DNA, and then the recombinant DNA is introduced into the DNA receiving bacteria can be applied (Chang, S. and Choen, SN, 1979. Mol. Gen. Genet. 168: 111-115; Bibb, MJ, Ward, JM and Hopwood, OA 1978. Nature 274: 398-400; Hinnen, A., Hicks, JB and Fink, GR 1978. Proc. Natl. Acad. Sci. USA 75: 1929-1933). Alternatively, an electric pulse method as reported for coryneform bacteria can be used (Japanese Patent Application Laid-Open No. 2-207791).

[0278] Increased activity of a protein can be confirmed by measuring the activity of the protein.

[0279] Increased protein activity can also be confirmed by confirming that the expression of a gene encoding the protein has increased. Increased gene expression can be confirmed by confirming that the transcription amount of the gene has increased, or by confirming that the amount of protein expressed from the gene has increased.

[0280] The confirmation that the transcription amount of a gene has been improved can be carried out by comparing the amount of mRNA transcribed from the gene with an unmodified strain such as a wild-type strain or a parent strain. As a method for evaluating the amount of mRNA, Northern hybridization, RT-PCR, microarray, RNA-seq, etc. (Sambrook, J., et al., Molecular Cloning: A Laboratory Manual / Third Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor (USA), 2001) can be cited. The amount of mRNA (e.g., the number of molecules per unit cell), for example, can be increased to more than 1.5 times, more than 2 times, or more than 3 times that of an unmodified strain.

[0281] Confirmation of increased protein quantity can be performed by Western blotting using antibodies (Sambrook, J., et al., Molecular Cloning: A Laboratory Manual / Third Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor (USA), 2001). The amount of protein (e.g., the number of molecules per unit cell) can be increased, for example, by 1.5 times, 2 times, or 3 times that of the unmodified strain.

[0282] The method for increasing the activity of a protein can be used to enhance the activity of any protein or to enhance the expression of any gene.

[0283] (1-5) Methods for reducing protein activity

[0284] Hereinafter, a method for reducing the activity of a protein will be described. It should be noted that the method for reducing the activity of a protein described below can also be used to disrupt the wild-type PhoS protein.

[0285] So-called "reduction in the activity of protein" means that the activity of the protein is reduced compared with the unmodified strain. So-called "reduction in the activity of protein" specifically means that the activity of the unit cell of the protein is reduced compared with the unmodified strain. Herein, so-called "unmodified strain" means a control strain that is not modified in a manner that reduces the activity of the target protein. As unmodified strains, wild-type strains and parent strains can be cited. In addition, as unmodified strains, specifically, standard strains (type strains) of each bacterial species can be cited. In addition, as unmodified strains, specifically, strains exemplified in the description of rod-shaped bacteria can be cited. That is, in one embodiment, the activity of the protein can be reduced compared with the standard strain (i.e., the standard strain of the species to which the bacterium of the present invention belongs). In addition, in another embodiment, the activity of the protein can be reduced compared with Corynebacterium glutamicum ATCC13032. In addition, in another embodiment, the activity of the protein can be reduced compared with Corynebacterium glutamicum ATCC 13869. In addition, in another embodiment, the activity of the protein can be reduced compared with Corynebacterium glutamicum AJ12036 (FERM BP-734). In addition, in another embodiment, the activity of the protein can be reduced compared with Corynebacterium glutamicum YDK010 strain. It should be noted that in "the activity of the protein is reduced", the situation that the activity of the protein disappears completely is also included. The so-called "the activity of the protein is reduced", more specifically, means that the number of molecules per unit cell of the protein is reduced and / or the function of the unit molecule of the protein is reduced compared with the unmodified strain. That is, the "activity" in the case of the so-called "the activity of the protein is reduced" is not limited to the catalytic activity of the protein, and can also mean the transcription amount (mRNA amount) or translation amount (amount of protein) of the gene encoding the protein. The so-called "the number of molecules per unit cell of the protein" can mean the average value of the unit cell of the number of molecules of the protein. It should be noted that, with respect to "the number of molecules per unit cell of the protein is reduced", the situation that the protein does not exist at all is also included. In addition, with respect to "the function of the unit molecule of the protein is reduced", the situation that the function of the unit molecule of the protein disappears completely is also included. The extent of reduction in protein activity is not particularly limited as long as the activity of the protein is reduced compared to the unmodified strain. The activity of the protein may be reduced, for example, to less than 50%, less than 20%, less than 10%, less than 5% or 0% of that of the unmodified strain.

[0286] Modifications that reduce the activity of a protein can be achieved, for example, by reducing the expression of a gene encoding the protein. The so-called "reduced expression of a gene" means that the expression of the gene is reduced compared to an unmodified strain. The so-called "reduced expression of a gene" specifically means that the expression level of the gene per cell is reduced compared to an unmodified strain. The so-called "expression level of a gene per cell" can mean the average value of the expression level of the gene per cell. The so-called "reduced expression of a gene" more specifically means that the transcription level (mRNA level) of the gene is reduced and / or the translation level (protein level) of the gene is reduced. As far as "reduced expression of a gene" is concerned, it also includes the situation where the gene is not expressed at all. It should be noted that "reduced expression of a gene" is also referred to as "weakened expression of a gene". The expression of a gene, for example, can be reduced to less than 50%, less than 20%, less than 10%, less than 5% or 0% of the unmodified strain.

[0287] The reduction of gene expression, for example, can be due to a reduction in transcription efficiency, or due to a reduction in translation efficiency, or due to a combination thereof. The reduction of gene expression, for example, can be achieved by modifying the expression regulatory sequence of the gene. The so-called "expression regulatory sequence" is a general term for sites that affect gene expression, such as promoters, Shine-Dalgarno (SD) sequences (also called ribosome binding sites (RBS)), and the spacer region between RBS and the start codon. The expression regulatory sequence, for example, can be determined using gene analysis software such as promoter search vectors and GENETYX. In the case of modifying the expression regulatory sequence, the expression regulatory sequence is preferably modified by more than 1 base, more preferably more than 2 bases, and particularly preferably more than 3 bases. The reduction of gene transcription efficiency can be achieved, for example, by weakly replacing the promoter of the gene on the chromosome with a weaker promoter. The so-called "weaker promoter" means a promoter whose transcription of the gene is weakened compared to the wild-type promoter that originally existed. As a weaker promoter, for example, an inducible promoter can be cited. That is, an inducible promoter can function as a weaker promoter under non-inducing conditions (for example, in the absence of an inducing substance). In addition, a part or all of the region of the expression regulatory sequence can be deleted (deleted). In addition, the reduction in gene expression can be achieved, for example, by manipulating factors related to expression control. Examples of factors related to expression control include low molecules (inducing substances, inhibitory substances, etc.), proteins (transcription factors, etc.), nucleic acids (siRNA, etc.) related to transcription and translation regulation. In addition, the reduction in gene expression can be achieved, for example, by introducing mutations into the coding region of the gene in a manner that reduces the expression of the gene. For example, the expression of a gene can be reduced by replacing the codons in the coding region of the gene with synonymous codons that are used at a lower frequency in the host. In addition, for example, the expression of the gene itself can be reduced by destroying the gene as described below.

[0288] In addition, modifications such as reducing the activity of a protein can be achieved, for example, by disrupting the gene encoding the protein. The so-called "gene disruption" means modifying the gene in such a way that a protein that functions normally is not produced. "No protein that functions normally is produced" includes situations where the gene cannot produce protein at all, and situations where the gene produces a protein whose function (e.g., activity, properties) of the average molecule is reduced or absent.

[0289] The destruction of a gene, for example, can be achieved by making the gene on the chromosome deleted (defective). The so-called "deletion of a gene" refers to the deletion of a part or all of the coding region of a gene. Further, the sequences before and after the coding region of the gene on the chromosome can be included to make the gene deleted as a whole. In the sequences before and after the coding region of the gene, for example, the expression regulatory sequence of the gene can be included. As long as the reduction of the activity of the protein can be achieved, the deleted region can be any region such as the N-terminal region (the region on the N-terminal side of the encoded protein), the internal region, and the C-terminal region (the region on the C-terminal side of the encoded protein). Generally, the gene can be reliably inactivated when the deleted region is longer. The deleted region, for example, can be a region of more than 10%, more than 20%, more than 30%, more than 40%, more than 50%, more than 60%, more than 70%, more than 80%, more than 90% or more than 95% of the total length of the coding region of the gene. In addition, the sequences before and after the deleted region are preferably inconsistent in reading frame. By inconsistent reading frames, frameshifts can be generated downstream of the deleted region.

[0290] In addition, gene disruption can be achieved, for example, by introducing an amino acid substitution (missense mutation), introducing a stop codon (nonsense mutation), or introducing an addition or deletion of 1 to 2 bases (frameshift mutation) into the coding region of a gene on a chromosome (Journal of Biological Chemistry 272: 8611-8617 (1997), Proceedings of the National Academy of Sciences, USA 95 5511-5515 (1998), Journal of Biological Chemistry 26 116, 20833-20839 (1991)).

[0291] In addition, the disruption of a gene can be achieved, for example, by inserting other base sequences into the coding region of a gene on a chromosome. The insertion site can be any region of the gene, and the gene can be reliably inactivated when the inserted base sequence is long. In addition, the sequences before and after the insertion site are preferably inconsistent in reading frame. By inconsistent reading frames, a frameshift can be generated downstream of the insertion site. As other base sequences, there is no particular limitation if the activity of the encoded protein is reduced or eliminated, and for example, marker genes such as antibiotic resistance genes and genes useful for the production of target products can be cited.

[0292] The disruption of a gene, in particular, can be implemented in a manner that causes the amino acid sequence of the encoded protein to be deleted (defective). In other words, such a modification that reduces the activity of a protein can be achieved, for example, by deleting the amino acid sequence of the protein (a part or all of the region of the amino acid sequence), specifically, by modifying the gene in a manner that encodes a protein that has deleted the amino acid sequence (a part or all of the region of the amino acid sequence). It should be noted that the so-called "deletion of the amino acid sequence of a protein" refers to the deletion of a part or all of the region of the amino acid sequence of the protein. In addition, the so-called "deletion of the amino acid sequence of a protein" refers to the situation where the original amino acid sequence in the protein becomes non-existent, and also includes the situation where the original amino acid sequence becomes another amino acid sequence. That is, for example, a region that becomes another amino acid sequence by frameshifting can be regarded as a deleted region. By deleting the amino acid sequence of a protein, typically the full length of the protein is shortened, and there are also situations where the full length of the protein does not change or is extended. For example, by deleting a part or all of the region of the coding region of a gene, the region encoded by the deleted region is deleted in the amino acid sequence of the encoded protein. In addition, for example, can be by importing stop codon to the coding region of gene, and in the amino acid sequence of coded protein, make the regional deletion encoded in the region downstream of this introduction position. In addition, for example, can make the regional deletion encoded in this frameshift position by the frameshift in the coding region of gene. About the position and length of the region deleted in the deletion of amino acid sequence, the explanation of the position and length of the region deleted in the deletion of gene can be applied.

[0293] With regard to modifying the gene on the chromosome as described above, for example, a disruptive gene modified in a manner that does not produce a protein that functions normally can be prepared, and a host is transformed by a recombinant DNA comprising the disruptive gene, and homologous recombination occurs between the disruptive gene and the wild-type gene on the chromosome, thus reaching by replacing the wild-type gene on the chromosome with the disruptive gene. At this time, for recombinant DNA, according to the characteristics such as the auxotrophy of the host, it is easy to operate when it includes a marker gene. As a disruptive gene, genes in a part or all of the region of the coding region of the gene missing, genes having been introduced into a missense mutation, genes having been introduced into a nonsense mutation, genes having been introduced into a frameshift mutation, genes having been inserted into insertion sequences such as a transposon and a marker gene can be enumerated. Even if the protein encoded by the disruptive gene is generated, it also has a three-dimensional structure different from the wild-type protein, and its function is reduced or disappears. The structure of the recombinant DNA used in homologous recombination is not particularly limited if homologous recombination occurs in a desired manner. For example, by transforming a host with a linear DNA containing a disrupted gene, i.e., a linear DNA having upstream and downstream sequences of a wild-type gene on a chromosome at both ends, homologous recombination occurs upstream and downstream of the wild-type gene, thereby replacing the wild-type gene with the disrupted gene. Gene disruption based on gene replacement using homologous recombination has been confirmed, and there are the following methods: a method called "Red-driven integration" (Datsenko, K. A, and Wanner, BL Proc. Natl. Acad. Sci. USA. 97: 6640-6645 (2000)), a method combining Red-mediated gene recombination and the excision mechanism derived from lambda phage (Cho, EH, Gumport, RI, Gardner, JFJ Bacteriol. 184: 5200-5203 (2002)) (see WO2005 / 010175), a method using a linear DNA, a method using a plasmid containing a temperature-sensitive replication origin, a method using a plasmid capable of conjugative transfer, a method using a suicide vector that does not retain a replication origin that functions in the host, and the like (U.S. Patent No. 6303383, Japanese Patent Application Laid-Open No. 05-007491). It should be noted that the method of modifying chromosomes using such homologous recombination is not limited to the disruption of target genes, but can be used for any modification of chromosomes such as modification of expression regulatory sequences.

[0294] In addition, modification such as reduction of protein activity can be performed, for example, by mutation treatment. Examples of mutation treatment include X-ray irradiation, ultraviolet irradiation, and treatment with mutagens such as N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), ethyl methanesulfonate (EMS), and methyl methanesulfonate (MMS).

[0295] The above-mentioned methods for reducing the activity of a protein may be used alone or in any combination.

[0296] The reduction in the activity of a protein can be confirmed by measuring the activity of the protein.

[0297] A decrease in protein activity can also be confirmed by confirming a decrease in the expression of a gene encoding the protein. A decrease in gene expression can be confirmed by confirming a decrease in the transcription level of the gene or a decrease in the amount of protein expressed from the gene.

[0298] The confirmation of the reduction of the transcription amount of a gene can be carried out by comparing the amount of mRNA transcribed by the gene with that of an unmodified strain. As a method for evaluating the amount of mRNA, Northern hybridization, RT-PCR, microarray, RNA-Seq, etc. (Sambrook, J., et al., Molecular Cloning: A Laboratory Manual / Third Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor (USA), 2001) can be cited. The amount of mRNA, for example, can be reduced to less than 50%, less than 20%, less than 10%, less than 5% or 0% of the unmodified strain.

[0299] The confirmation of the reduction of the amount of protein can be carried out by performing SDS-PAGE and confirming the intensity of the separated protein bands. In addition, the confirmation of the reduction of the amount of protein can be carried out by Western blotting using antibodies (Sambrook, J., et al., Molecular Cloning: A Laboratory Manual / Third Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor (USA), 2001). The amount of protein (e.g., the number of molecules per unit cell), for example, can be reduced to less than 50%, less than 20%, less than 10%, less than 5% or 0% of the unmodified strain.

[0300] Whether a gene is disrupted can be confirmed by determining the base sequence of a part or all of the gene, the restriction enzyme map, or the full length, etc., according to the means used for the disruption.

[0301] The method for reducing the activity of a protein can be used to reduce the activity of any protein or reduce the expression of any gene.

[0302] (1-6) Production of bbFGF

[0303] By culturing the bacterium of the present invention, bbFGF is secreted and produced, thereby obtaining a culture containing bbFGF.

[0304] As for the culture medium used for cultivation, there is no particular limitation as long as the bacteria of the present invention can proliferate and produce bbFGF. As the culture medium, for example, a common culture medium used for the cultivation of bacteria such as rod-shaped bacteria can be used. As the culture medium, specifically, for example, a common culture medium containing a carbon source, a nitrogen source, and inorganic ions can be cited. Organic trace nutrients such as vitamins and amino acids can be added to the culture medium as needed. As for the culture conditions, there is no particular limitation as long as the bacteria of the present invention can proliferate and produce bbFGF. As for the cultivation, for example, it can be carried out under the common conditions used for the cultivation of bacteria such as rod-shaped bacteria. As for the type, concentration and cultivation of the culture medium components, for example, they can be appropriately set according to various conditions such as the type of rod-shaped bacteria.

[0305] As a carbon source, for example, carbohydrates such as glucose and sucrose, organic acids such as acetic acid, alcohols or other appropriate carbon sources can be used. As a nitrogen source, for example, ammonia gas, ammonia water, ammonium salts or other appropriate nitrogen sources can be used. As inorganic ions, for example, calcium ions, magnesium ions, phosphate ions, potassium ions or iron ions can be used as needed. Cultivation can be carried out for about 1 to 7 days under a suitable range of pH 5.0 to 8.5, 15° C. to 37° C. and aerobic conditions. In addition, the culture conditions in the production of L-amino acids in rod-shaped bacteria and the conditions described in the production method of proteins using other signal peptides that rely on the Sec system and Tat system can be used (see WO01 / 23591, WO2005 / 103278). In addition, when an inducible promoter is used for the expression of genes such as the bbFGF gene, the expression of the gene can be appropriately induced. By culturing the bacteria of the present invention under such conditions, bbFGF is secreted and produced, so that a culture containing bbFGF can be obtained.

[0306] The secretion and production of bbFGF can be confirmed by subjecting the components containing the culture supernatant and / or the bacterial surface layer as samples to SDS-PAGE and determining the molecular weight of the separated protein band. In addition, the secretion and production of bbFGF can be confirmed by using the components containing the culture supernatant and / or the bacterial surface layer as samples and by Western blotting using antibodies (Molecular cloning (Cold Spring Harbor Laboratory Press, Cold Spring Harbor (USA), 2001)). In addition, the secretion and production of bbFGF can be confirmed by detecting the amino acid sequence of the N-terminus of the secreted protein using protein sequencing. In addition, the secretion and production of bbFGF can be confirmed by determining the mass of the secreted protein using a mass analyzer. In addition, in the case where bbFGF has an enzyme or some physiological activity that can be measured, the secretion and production of bbFGF can be confirmed by using the components containing the culture supernatant and / or the bacterial surface layer as samples to measure the physiological activity of bbFGF.

[0307] As for the culture containing bbFGF (specifically, the culture containing bbFGF obtained by secretion), it can be used as an active ingredient in the production of cultured meat as it is or after being subjected to sterilization, reduction, purification, solvent replacement, drying and the like as appropriate. These treatments can be implemented alone or in appropriate combination. For example, at least sterilization can be implemented. "Sterilization" can mean removing the bacterial cells of the bacteria of the present invention from the culture containing bbFGF. As for sterilization, for example, it can be implemented by solid-liquid separation means such as natural sedimentation, centrifugation, and filtration. As for filtration, for example, it can be implemented using a filter such as a PVDF membrane. "Reduction" can mean the reduction of bbFGF, specifically, placing a component containing bbFGF (such as a culture, a culture supernatant, or a purified bbFGF solution) in a reduced state. As for reduction, for example, it can be implemented by adding a reducing agent such as DTT. "Purification" can mean the purification of bbFGF, specifically, purifying bbFGF from a component containing bbFGF (such as a culture or a culture supernatant). "Purification of bbFGF" may mean separating bbFGF from components other than bbFGF. Components other than bbFGF are also referred to as "inclusions". Examples of inclusions include substances contained in components containing bbFGF (e.g., culture supernatant). It should be noted that sterilization does not correspond to "purification of bbFGF". In other words, the bacterial cells of the present invention do not correspond to "inclusions" in the purification of bbFGF. As for purification, for example, it can be implemented by protein separation and purification methods such as salting out, ethanol precipitation, ultrafiltration, gel filtration chromatography, ion exchange chromatography, reverse phase chromatography, affinity chromatography, etc. In another embodiment, purification of bbFGF may not be implemented. The term "not implementing purification of bbFGF" can be used interchangeably with the term "bbFGF is not purified". "Not implementing purification of bbFGF" may mean, for example, using bbFGF as an active ingredient in a state where 70% (w / w) or more, 80% (w / w) or more, 90% (w / w) or more, 95% (w / w) or more, 97% (w / w) or more, or 99% (w / w) or more of impurities remain (i.e., coexisting with bbFGF). In another embodiment, in particular, purification of bbFGF by chromatography may not be implemented. By not implementing purification of bbFGF (particularly purification by chromatography), for example, the production cost of bbFGF can be suppressed, and thus the production cost of cultured meat can be suppressed. In the case of bbFGF produced using coryneform bacteria as an expression host, it can be suitably used for the culture of animal cells (specifically, the production of cultured meat) even if it is not purified to a high purity by chromatography or the like. "Solvent replacement" may mean replacement of a liquid portion constituting a component containing bbFGF (e.g., a culture, a culture supernatant, or a purified bbFGF solution). For solvent replacement, a buffer such as PBS can be used. The buffer may contain a reducing agent such as DTT."Drying" may mean drying of bbFGF, specifically, drying a component containing bbFGF (e.g., a culture, a culture supernatant, or a purified bbFGF solution). Drying can be carried out, for example, by drying means such as freeze drying and spray drying. In the case where bbFGF is secreted on the surface of the bacteria, bbFGF can be solubilized by solubilization means such as increasing the salt concentration and using a surfactant. The component containing solubilized bbFGF can be used as an active ingredient in the production of cultured meat, as is the case with the culture containing bbFGF, or after being subjected to sterilization, reduction, purification, solvent replacement, drying, or the like as appropriate.

[0308] The shape of the active ingredient is not particularly limited. The active ingredient may be in any form, such as powder, tablet, paste, liquid, etc. For example, a component containing bbFGF may be dried and powdered to be used as the active ingredient.

[0309] (2) Method of the present invention

[0310] The method of the present invention is a method for producing cultured meat, which includes a step of culturing animal cells in the presence of an active ingredient (i.e., bbFGF produced by using coryneform bacteria as an expression host). This step is also referred to as an "animal cell culturing step". Specifically, the animal cell culturing step may be a step of culturing animal cells in the presence of an active ingredient to form cultured meat.

[0311] Animal cells are not particularly limited as long as they can form cultured meat by culture. Cultured meat can be mainly composed of muscle tissue. Therefore, "animal cells can form cultured meat by culture" may mean, for example, that animal cells can differentiate by culture to form muscle tissue, specifically, that animal cells can differentiate into myotube cells by culture to form muscle tissue. Examples of animal cells include stem cells such as mesenchymal stem cells, embryonic stem cells (ES cells), and artificial pluripotent stem cells (iPS cells), and myoblasts. Examples of animals include animals for edible meat. Examples of animals for edible meat include cattle, sheep, goats, pigs, and rabbits. Examples of animals for edible meat include cattle and pigs.

[0312] The culture of animal cells is carried out in the presence of an active ingredient. “The culture of animal cells is carried out in the presence of an active ingredient” may mean, for example, that the medium used in the culture of animal cells contains an active ingredient. “The culture of animal cells is carried out in the presence of an active ingredient” may mean, for example, that the active ingredient is provided to the culture system during the culture of animal cells.

[0313] As for the composition of the culture medium and the culture conditions, there is no particular limitation as long as the cultured meat is formed by culturing the cells, except that the culture is carried out in the presence of an active ingredient. The composition of the culture medium and the culture conditions can be appropriately set according to various conditions such as the type of animal cells. The culture is carried out in the presence of an active ingredient, and in addition, it can be carried out using a common culture medium and common conditions used in the formation of muscle tissue (e.g., the production of cultured meat) by differentiation of animal cells as it is or with appropriate modifications.

[0314] Cultivation can be implemented, for example, using a liquid culture medium. Cultivation can be implemented by batch culture, fed-batch culture, continuous culture, or a combination thereof. As continuous culture, perfusion culture and chemostat culture can be cited. It should be noted that the culture medium at the beginning of the culture is also referred to as "initial culture medium" or "basal culture medium". In addition, the culture medium provided to the culture system (e.g., initial culture medium) in fed-batch culture is also referred to as "feed medium". In addition, the culture medium provided to the culture system (e.g., initial culture medium) in continuous culture (not limited to perfusion culture here) is also referred to as "perfusion medium". In addition, feeding medium or perfusion medium is provided to the culture system in fed-batch culture or continuous culture, which is referred to as "culture medium supply". Culture medium supply can be implemented throughout the entire period of culture, or it can be implemented only during a portion of the culture. In addition, culture medium supply can be implemented continuously or intermittently. During culture (especially continuous culture such as perfusion culture), extraction of the culture fluid can be implemented. The extraction of the culture solution can be carried out throughout the entire culture period, or can be carried out only during a portion of the culture period. The extraction of the culture solution can be carried out continuously or intermittently. The extraction of the culture solution and the supply of the culture medium can be carried out simultaneously or at different times. As for the culture, for example, it can be carried out three-dimensionally using a scaffold material that conforms to the shape of the cultured meat to be formed.

[0315] The culture medium used for the culture may be, for example, a basal medium, a fed-batch medium, and a perfusion medium, each independently selected.

[0316] The medium used for the culture may be a commercially available medium or a medium prepared appropriately.

[0317] Examples of the medium used for the culture include a medium containing components necessary for the culture of animal cells (for example, a carbon source, a nitrogen source, an inorganic salt, etc.).

[0318] Specific examples of the medium used for the culture include Dulbecco's Modified Eagle's Medium (DMEM), Ham's Nutrient Mixture F12, DMEM / F12 medium, McCoy's 5A medium, Minimum Essential Medium (MEM), Eagle's Minimum Essential Medium (EMEM), alpha Modified Eagle's Minimum Essential Medium (αMEM), Roswell Park Memorial Institute (RPMI) 1640 medium, Iscove's Modified Dulbecco's Medium (IMDM), MCDB131 medium, William's Medium E, and Fischer's Medium.

[0319] In addition, as a medium used for culture (for example, a medium used in the culture of stem cells (especially pluripotent stem cells) in particular), specifically, STEMPRO (registered trademark) hESC SFM medium (Life Technologies), mTeSR1 medium (STEMCELL Technologies), TeSR2 medium (STEMCELL Technologies), TeSR-E8 medium (STEMCELL Technologies), Essential 8 medium (Life Technologies), HEScGRO (trademark) Serum-Free Medium for hES cells (Millipore), PluriSTEM (trademark) Human ES / iPS Medium (EMD Millipore), NutriStem (registered trademark) hESC XF medium (Biological Industries Israel Beit-Haemek), NutriStem (trademark) XF / FF Culture Medium (Stemgent), AF NutriStem (registered trademark) hESC XF medium (Biological Industries Israel Beit-Haemek), S-medium (DSPHARMA BIOMEDICAL Co., Ltd.), StemFit (registered trademark) AK03N medium (AJINOMOTO Co., Ltd.), hESF9 medium, hESF-FX medium, CDM medium, DEF-CS 500 Xeno-Free 3D Spheroid Culture Medium (Cellartis), StemFlex medium (Thermo Fisher Scientific), etc.

[0320] In addition, other commercially available culture media include animal cell culture media such as CELLiST Basal Media BASAL3, BASAL4P, BASAL10 (AJINOMOTO Co., Ltd.), Opti-MEM (Thermo Fisher Scientific), RPMI 1640 (Thermo Fisher Scientific), CD293 (Thermo Fisher Scientific), CHO-S-SFMII (ThermoFisher Scientific), CHO-SF (Sigma-Aldrich), EX-CELL CD CHO (Sigma-Aldrich), EX-CELLTM302 (Sigma-Aldrich), IS CHO-CD (Irvine Scientific), and IS CHO-CDXP (IrvineScientific).

[0321] The above-mentioned medium can be used for culture by adding, for example, an effective ingredient.

[0322] The culture medium can contain various culture medium components. As culture medium components, carbon sources, amino acid sources, peptides, proteins, vitamins, fatty acids, lipids, inorganic components, pH buffers, growth factors, cytokines, hormones, cell adhesion factors, extracellular matrix components, serum, antibiotics, gene expression inducers can be enumerated. For example, such culture medium components can be necessary or effective for the survival or proliferation of animal cells. Such culture medium components can be contained in advance in the culture medium as described above, or can be added to the culture medium as described above.

[0323] Examples of the carbon source include sugars such as glucose, fructose, sucrose, and maltose.

[0324] As the amino acid source, amino acids can be mentioned. In addition, peptides and proteins can be an example of amino acid sources. As amino acids, glycine, alanine, valine, leucine, isoleucine, cysteine, methionine, phenylalanine, tyrosine, tryptophan, histidine, lysine, arginine, serine, threonine, aspartic acid, glutamic acid, asparagine, glutamine, proline, ornithine can be mentioned. The amino acid can be, for example, L-form.

[0325] As peptides, dipeptides and tripeptides can be mentioned. As peptides, specifically, glycylglycylglycine and soybean peptide can be mentioned. The description of amino acids can also be applied to the amino acids constituting peptides.

[0326] Examples of the protein include albumin and transferrin.

[0327] Examples of the vitamins include vitamin A, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B7, vitamin B9, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, and precursors thereof.

[0328] Examples of the fatty acid include oleic acid, arachidonic acid, and linoleic acid.

[0329] Examples of lipids include cholesterol.

[0330] Examples of the inorganic component include sodium, potassium, calcium, magnesium, phosphorus, and various trace elements (e.g., Co, Cu, F, Fe, Mn, Mo, Ni, Se, Si, Ni, Bi, V, and Zn). Specifically, examples of the inorganic component include inorganic salts such as sodium chloride, potassium chloride, calcium chloride, magnesium sulfate, and sodium dihydrogen phosphate.

[0331] Examples of the pH buffer include sodium bicarbonate, phosphate, N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), and N-[tris(hydroxymethyl)methyl]glycine (Tricine).

[0332] Examples of growth factors include fibroblast growth factor (FGF), hepatocyte growth factor (HGF), epidermal growth factor (EGF), transforming growth factor (TGF)-α, transforming growth factor (TGF)-β, vascular endothelial growth factor (VEGF), activin A, and insulin-like growth factor-1 (IGF-1).

[0333] Examples of cytokines include interleukins.

[0334] Examples of the hormone include dexamethasone, hydrocortisone, estradiol, progesterone, glucagon, and insulin.

[0335] Examples of the cell adhesion factor or the extracellular matrix component include Type I collagen, Type II collagen, fibronectin, laminin, poly-L-lysine, and poly-D-lysine.

[0336] Examples of the antibiotics include amphotericin B, kanamycin, gentamicin, streptomycin, and penicillin.

[0337] In another embodiment, the culture medium may be substantially free of serum. For example, the culture medium may be substantially free of serum during the entire period of culture. "The culture medium substantially free of serum" may mean that the content of serum in the culture medium is 1% (w / w) or less, 0.1% (w / w) or less, 0.01% (w / w) or less, or 0.001% (w / w) or less, and may also include a situation where the content of serum in the culture medium is 0 (zero) (i.e., the culture medium does not contain serum).

[0338] Various components such as effective ingredients can be contained in the initial culture medium, the feed medium, the perfusion medium or a combination thereof. That is, during the culture process, various components such as effective ingredients can be provided to the culture medium alone or in any combination. These components can be provided once or multiple times, or they can be provided continuously. The composition (for example, the type and / or concentration of the components contained) of the initial culture medium, the feed medium and the perfusion medium can be the same or different. That is, the type of components contained in the initial culture medium can be the same as the type of components contained in the feed medium or the perfusion medium, or it can be different. In addition, the concentration of each component contained in the initial culture medium can be the same as the concentration of each component contained in the feed medium or the perfusion medium, or it can be different. For example, in the case where the feed medium is used for perfusion culture, the initial culture medium can be the same as the composition of the feed medium. In addition, two or more feed mediums or perfusion mediums with different compositions (for example, the types and / or concentrations of the components contained) can be used. For example, in the case where the supply of the feed medium or the perfusion medium is implemented intermittently multiple times, the composition of the feed medium or the perfusion medium can be the same each time, or it can be different. Furthermore, various components such as active ingredients may be provided to the culture medium in a form such as powder that is not contained in the fed-batch medium or the perfusion medium.

[0339] The inoculation amount of animal cells at the start of culture can be, for example, 1×10 3 cells / mL or more, 1×10 4 cells / mL or more, 1×10 5 cells / mL or more, 1×10 6 cells / mL or above or 1×10 7 cells / mL or more, or 1×108 cells / mL or less, 1×10 7 cells / mL or less, 1×10 6 cells / mL or less, 1×10 5 cells / mL or less or 1×10 4 The inoculation amount of animal cells at the start of culture can be, for example, 1×10 cells / mL or less, or a combination that does not conflict with each other. 3 ~1×10 4 cells / mL,1×10 4 ~1×10 5 cells / mL,1×10 5 ~1×10 6 cells / mL,1×10 6 ~1×10 7 cells / mL or 1×10 7 ~1×10 8 The inoculation amount of animal cells at the start of culture can be, for example, 1×10 3 ~1×10 8 cells / mL,1×10 4 ~1×10 7 cells / mL or 1×10 5 ~1×10 6 For the number of live cells, for example, the live / non-living cell automatic analyzer Vi-CELL can be used. TM XR (BECKMANCOULTER) was used for measurement.

[0340] The culture can be carried out in an atmosphere containing CO2, such as 5-15% CO2. The pH of the culture medium can be, for example, near neutral. "Near neutral" can mean, for example, pH 6-8, pH 6.5-7.5 or pH 6.8-7.2. During the culture, the pH of the culture medium can be adjusted as needed. The pH of the culture medium can be adjusted using various alkaline or acidic substances such as ammonia gas, ammonia water, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, magnesium carbonate, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, etc. The culture temperature can be, for example, 30-38°C. The culture period may be, for example, 0.5 days or more, 1 day or more, 2 days or more, 3 days or more, 4 days or more, 5 days or more, 6 days or more, 7 days or more, 8 days or more, 9 days or more, 10 days or more, 12 days or more, 15 days or more, or 20 days or more, or 60 days or less, 50 days or less, 40 days or less, 30 days or less, 25 days or less, 20 days or less, 15 days or less, 12 days or less, 10 days or less, 9 days or less, 8 days or less, or 7 days or less, or any combination that does not contradict each other. Specifically, for example, the culture period may be 1 to 60 days, 3 to 25 days, or 5 to 20 days. For example, the culture may be continued until the cultured meat is formed to the desired degree.

[0341] The concentration of the active ingredient in the culture medium may be, for example, 0.01 ng / mL or more, 0.02 ng / mL or more, 0.05 ng / mL or more, 0.1 ng / mL or more, 0.2 ng / mL or more, 0.5 ng / mL or more, 1 ng / mL or more, 2 ng / mL or more, 5 ng / mL or more, 10 ng / mL or more, 15 ng / mL or more, 20 ng / mL or more, or 25 ng / mL or more; or 30 ng / mL or less, 25 ng / mL or less, 20 ng / mL or less, 15 ng / mL or less, 10 ng / mL or less, 5 ng / mL or less, 2 ng / mL or less, 1 ng / mL or less, 0.5 ng / mL or less, 0.2 ng / mL or less, 0.1 ng / mL or less, 0.05 ng / mL or less, or 0.02 ng / mL or less; or any combination that is not contradictory to each other may be used. The concentration of the active ingredient in the culture medium may be, for example, 0.01 to 0.02 ng / mL, 0.02 to 0.05 ng / mL, 0.05 to 0.1 ng / mL, 0.1 to 0.2 ng / mL, 0.2 to 0.5 ng / mL, 0.5 to 1 ng / mL, 1 to 2 ng / mL, 2 to 5 ng / mL, 5 to 10 ng / mL, 10 to 15 ng / mL, 15 to 20 ng / mL, 20 to 25 ng / mL, or 25 to 30 ng / mL. The concentration of the active ingredient in the culture medium may be, for example, 0.01 to 30 ng / mL, 0.02 to 20 ng / mL, or 0.05 to 15 ng / mL.

[0342] Various components such as active ingredients may be contained in the culture medium during the entire period of culture, or may be contained in the culture medium only during a portion of the culture period. That is, "culture is carried out in a culture medium containing a certain component" or "a certain component is contained in the culture medium during culture" means that the component is contained in the culture medium at least during a portion of the culture period, and the component does not need to be contained in the culture medium during the entire period of culture. With regard to various components such as active ingredients, for example, they may be contained in the culture medium at the beginning of culture, or they may be provided to the culture medium after the beginning of culture. In addition, with regard to various components such as active ingredients, for example, they may be contained in the culture medium at the beginning of culture, and they may be further provided to the culture medium after the beginning of culture (for example, after the consumption of the active ingredient).

[0343] As for various components such as effective ingredients, for example, they can be contained in the culture medium at the concentration as described above during the entire period of culture, or they can be contained in the culture medium at the concentration as described above only during a part of the culture. That is, "culture is carried out in a culture medium containing a certain component at a certain concentration", "a certain component is contained in the culture medium at a certain concentration during culture" or "the concentration of a certain component in the culture medium during culture is a certain concentration" means that the concentration of the component in the culture medium is within the range of the concentration as long as it is within at least a part of the culture period, and the concentration of the component in the culture medium does not need to be within the range of the concentration during the entire period of culture. As for various components such as effective ingredients, for example, they can be contained in the culture medium at the concentration as described above at the beginning of culture, or they can be provided to the culture medium in a manner that becomes the concentration as described above after the beginning of culture. In addition, as for various components such as effective ingredients, for example, they can be contained in the culture medium at the concentration as described above at the beginning of culture, and they can be further provided to the culture medium in a manner that becomes the concentration as described above after the beginning of culture (for example, after the consumption of the component).

[0344] The length of "a portion of the culture period" is not particularly limited as long as the proliferation promoting effect is obtained. The length of "a portion of the culture period" can be appropriately set according to various conditions such as the type of animal cells and the length of the culture period. "A portion of the culture period" can be, for example, a period of more than 10%, more than 20%, more than 30%, more than 40%, more than 50%, more than 60%, more than 70%, more than 80%, more than 90%, more than 95%, more than 97% or more than 99% of the entire culture period. In addition, "a portion of the culture period" can be, for example, a period of more than 10%, more than 20%, more than 30%, more than 40%, more than 50%, more than 60%, more than 70%, more than 80%, more than 90%, more than 95%, more than 97% or more than 99% of the entire culture period after the animal cells differentiate into myotube cells. In addition, the “partial period” may be, for example, a period of 0.5 days or more, 1 day or more, 2 days or more, 3 days or more, 4 days or more, 5 days or more, 6 days or more, 7 days or more, 8 days or more, 9 days or more, 10 days or more, 12 days or more, or 15 days or more.

[0345] In addition, as for the concentration of various components such as the effective ingredient in the culture medium, for example, as an average value throughout a specific period in the culture, it can be set to the concentration as described above. That is, "the culture is implemented in a culture medium containing a certain component at a certain concentration", "a certain component is contained in the culture medium at a certain concentration during the culture" or "the concentration of a certain component in the culture medium during the culture is a certain concentration" can mean that the average value of the concentration of the component in the culture medium during the specific period in the culture is within the range of the concentration. "The average value of the concentration of a certain component in the culture medium during the specific period in the culture" is not particularly limited as long as it is a value that can grasp the change of the concentration of the component during the specific period in the culture, for example, the average value of the concentration of the component in the culture medium measured every 60 minutes, every 30 minutes, every 20 minutes or every 10 minutes during the specific period in the culture. As the "specific period in the culture", the entire period of the culture and the period of a part of the culture can be cited. For the "period of a part of the culture", it is as described above.

[0346] Various components such as active ingredients may be provided to the culture medium throughout the entire period of culture, or may be provided to the culture medium only during a portion of the culture period. The "part of the culture period" is as described above. Various components such as active ingredients, for example, may be provided to the culture medium continuously, or may be provided to the culture medium intermittently. Various components such as active ingredients, for example, may be provided to the culture medium every day, or may be provided to the culture medium at intervals of multiple days.

[0347] With regard to the concentration of various components such as the active ingredient in the feed medium or the perfusion medium, for example, it can be within the range of the concentration of the component in the culture medium as described above. In addition, with regard to the concentration of various components such as the active ingredient in the feed medium or the perfusion medium, for example, it can be more than 1 times, more than 1.1 times, more than 1.3 times, more than 1.5 times, more than 2 times, more than 3 times, more than 5 times, more than 7 times, more than 10 times, more than 15 times, or more than 20 times the concentration of the component in the culture medium as described above, or it can be less than 100 times, less than 70 times, less than 50 times, less than 30 times, less than 20 times, less than 15 times, less than 10 times, less than 7 times, less than 5 times, less than 3 times, or less than 2 times, or it can be a combination that does not contradict each other. The concentration of various components such as the effective ingredient in the feed medium or the perfusion medium may be, for example, 1 to 2 times, 1.1 to 2 times, 1.3 to 2 times, 1.5 to 2 times, 2 to 3 times, 3 to 5 times, 5 to 7 times, 7 to 10 times, 10 to 15 times, 15 to 20 times, 20 to 30 times, 20 to 50 times, 20 to 70 times, or 20 to 100 times the concentration of the component in the above-mentioned medium. The concentration of various components such as the effective ingredient in the feed medium or the perfusion medium may be, for example, 1 to 100 times, 2 to 50 times, or 5 to 20 times the concentration of the component in the above-mentioned medium.

[0348] The concentration of various components such as active ingredients can be measured, for example, by known methods for detection or identification of compounds, such as HPLC, UPLC, LC / MS, GC / MS, and NMR.

[0349] Animal cells are cultured in the above manner to obtain cultured meat.

[0350] Example

[0351] Hereinafter, the present invention will be further specifically described with reference to non-limiting examples.

[0352] (Reference Example 1) Construction of Corynebacterium glutamicum lacking the O-mannosyltransferase gene pmt1

[0353] (1) Construction of the pmt1 gene deletion vector pBS5TΔpmt1

[0354] It is known that O-glycosylation occurs in secretory proteins expressed in Corynebacterium glutamicum as a host, and that the ability to modify secretory proteins by modifying O-glycosylation can be abolished by deleting the protein O-mannosyltransferase PMT1 (Martina Mahne et al., The Corynebacterium glutamicum gene pmt encoding aglycosyltransferase related to eukaryotic protein-O-mannosyltransferases isessential for glycosylation of the resuscitation promoting factor (Rpf2) and other secreted proteins. FEMS Microbiol Lett. 2006 Jun;259(2):226-33.).

[0355] In addition, the genome sequence of Corynebacterium glutamicum ATCC 13869 and the base sequence of the pmt1 gene encoding the protein O-mannosyltransferase PMT1 have been determined (GenBank Accession No. AP017557, NCBI locus_tag CGBL_0109730). The base sequence of the pmt1 gene of Corynebacterium glutamicum ATCC 13869 and the amino acid sequence of PMT1 encoded by the gene are shown in SEQ ID NOs. 39 and 40, respectively.

[0356] PurElute will be used TMChromosomal DNA of Corynebacterium glutamicum ATCC13869 strain prepared by Genomic DNA Kit (EdgeBio) was used as a template, and primers of SEQ ID NO.41 and SEQ ID NO.42 were used for about 1 kbp upstream of the 5' side of the pmt1 gene, and primers of SEQ ID NO.43 and SEQ ID NO.44 were used for about 1 kbp downstream of the 3' side of the pmt1 gene, respectively, and amplified by PCR method. Next, a DNA fragment of about 2 kbp fused with the two DNA fragments was obtained by PCR method using the two amplified DNA fragments as templates and DNA shown in SEQ ID NO.41 and SEQ ID NO.44 as primers. Pyrobest (registered trademark) DNA polymerase (Takara Bio) was used in PCR, and the reaction conditions were carried out according to the protocol recommended by the manufacturer. By inserting this DNA fragment into the SmaI site of pBS5T described in WO2006 / 057450, a vector pBS5TΔpmt1 for pmt1 gene deletion was obtained. DNA Ligation Kit (Mighty Mix) (Takara Bio) was used for the ligation reaction, and the reaction conditions were carried out according to the protocol recommended by the manufacturer.

[0357] (2) Construction of a pmt1 gene-deficient strain of Corynebacterium glutamicum YDK0107

[0358] The Corynebacterium glutamicum YDK0107 strain described in WO2016 / 171224 was transformed using pBS5TΔpmt1 constructed in (1). The Corynebacterium glutamicum YDK0107 strain is a natural mutant strain obtained by using the Corynebacterium glutamicum YDK010 strain as a parent strain and in which the W302C mutation was introduced into the phoS gene (WO2016 / 171224). The Corynebacterium glutamicum YDK010 strain is a deletion strain of the cell surface protein CspB of Corynebacterium glutamicum AJ12036 (FERM BP-734) (WO2002 / 081694). From the obtained transformants, strain screening was performed according to the method described in WO2006 / 057450, and the YDK0107Δpmt1 strain lacking the pmt1 gene was obtained.

[0359] (Example 1) Secretory expression of bovine basic fibroblast growth factor (bbFGF) based on Corynebacterium glutamicum

[0360] (1-1) Construction of a secretory expression plasmid for bbFGF with the TorA signal sequence added

[0361] The amino acid sequence of bovine basic fibroblast growth factor-2 (hereinafter referred to as bbFGF) has been confirmed (UniProt Accession No. P03969). The amino acid sequence is shown in SEQ ID NO.46.

[0362] Taking into account the codon usage frequency of Corynebacterium glutamicum, the base sequence encoding bbFGF was designed. The designed base sequence is shown in SEQ ID NO.45.

[0363] Next, in order to achieve secretory expression of bbFGF based on Corynebacterium glutamicum, a fusion protein (TorAss-bbFGF) of the signal peptide 39 amino acid residues of the TorA protein (UniProt Accession No. P33225) from Escherichia coli and bbFGF was designed. The designed base sequence and amino acid sequence encoding TorAss-bbFGF are shown in SEQ ID NO.47 and SEQ ID NO.48, respectively. The promoter of the cspB gene derived from Corynebacterium glutamicum ATCC13869 strain was connected upstream of the base sequence encoding TorAss-bbFGF, and a KpnI site was added to the 5'-side and an ApaI site was added to the 3'-side to design the expression cassette of TorAss-bbFGF and perform full synthesis.

[0364] By inserting the expression cassette of TorAss-bbFGF into the KpnI-ApaI site of pPK10 described in WO2021 / 112249, pPK10_TorAss-bbFGF, which is a secretory expression plasmid of bbFGF using the TorA signal sequence, was constructed. The results of the base sequence determination of the inserted fragment confirmed that the expression cassette of TorAss-bbFGF designed as above was constructed. The base sequence was determined using BigDye (registered trademark) Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and 3500xL Genetic Analyzer (Applied Biosystems).

[0365] (1-2) Secretory Expression of bbFGF in Corynebacterium glutamicum

[0366] The Corynebacterium glutamicum YDK0107Δpmt1 strain described in Reference Example 1 was transformed using pPK10_TorAss-bbFGF to obtain the YDK0107Δpmt1 / pPK10_TorAss-bbFGF strain. The obtained transformant was cultured at 30°C for 72 hours in a MMTG liquid medium (120 g of glucose, 3 g of magnesium sulfate heptahydrate, 30 g of ammonium sulfate, 1.5 g of potassium dihydrogen phosphate, 0.03 g of iron sulfate heptahydrate, 0.03 g of manganese sulfate pentahydrate, 0.45 mg of thiamine hydrochloride, 0.45 mg of biotin, 0.15 g of DL-methionine, soybean hydrochloride hydrolyzate (total nitrogen content 0.2 g), 50 g of calcium carbonate, adjusted to 1 L with water, pH 7.0) containing 25 mg / L of kanamycin. After the culture was completed, each culture solution was centrifuged and 6.5 μL of the obtained culture supernatant was subjected to reducing SDS-PAGE using NuPAGE (registered trademark) 12% Bis-Tris Gel (Thermo Fisher Scientific) and then stained with Quick-CBB (Wako). As a result, a protein band presumed to be bbFGF was detected in the culture supernatant of the YDK0107Δpmt1 / pPK10_TorAss-bbFGF strain ( Figure 1 , Lanes 2-5).

[0367] (Example 2) Evaluation of the biological activity of bovine basic fibroblast growth factor (bbFGF) secreted by Corynebacterium glutamicum-1

[0368] (2-1) Preparation of crude purified bbFGF fraction A

[0369] Corynebacterium glutamicum YDK0107Δpmt1 / pPK10_TorAss-bbFGF strain was cultured in a fermentation tank according to a known method (Hiroshi Itaya and Yoshimi Kikuchi. Secretion of Streptomyces mobaraensis pro-transglutaminase by coryneform bacteria. ApplMicrobiol Biotechnol. 2008; 78(4): 621-625.). The centrifuged supernatant of the culture solution was diluted 6.6 times with ultrapure water and aseptically filtered using a 0.2 μm PVDF membrane filter. This was used as a crude purified fraction A and was frozen at -80°C until the biological activity was evaluated.

[0370] (2-2) Activity determination of crude purified fraction A of bbFGF

[0371] The activity of the crude purified fraction A obtained above was measured by cell proliferation activity using BALB / c 3T3 cells. As an activity standard, the human bFGF international standard (WHO International Standard FGF-2, Human, rDNA derived, NIBSC code: 90 / 712, Specific Activity; 8.0 × 10 5 U / mg). The bbFGF concentration in the crude purified fraction A was determined by reverse phase HPLC using bFGF (basic FGF) Solution, Human, Recombinant (154 aa), Animal-Free (Cat#19155-07 manufactured by NACALAITESQUE) as a standard. As a result, the cell proliferation activity value (Specific Activity) of the crude purified fraction A was 3.6×10 6 U / mg.

[0372] (Example 3) Evaluation of the biological activity of bovine basic fibroblast growth factor (bbFGF) secreted by Corynebacterium glutamicum-2

[0373] (3-1) Preparation of crude purified bbFGF fraction B

[0374] Corynebacterium glutamicum YDK0107Δpmt1 / pPK10_TorAss-bbFGF strain was cultured in a fermentation tank according to a known method (Hiroshi Itaya and Yoshimi Kikuchi. Secretion of Streptomyces mobaraensis pro-transglutaminase by coryneform bacteria. ApplMicrobiol Biotechnol. 2008; 78(4): 621-625.). Dithiothreitol was added to the centrifuged supernatant of the culture solution to a concentration of 1.03 mg / mL. After standing for 15 minutes, it was diluted 6.6 times with ultrapure water and aseptically filtered using a 0.2 μm PVDF membrane filter. This was used as a crude purified component B and was frozen at -80°C until the biological activity was evaluated.

[0375] (3-2) Activity determination of crude purified fraction B of bbFGF

[0376] The activity of the crude purified fraction B obtained above was measured by cell proliferation activity using BALB / c 3T3 cells. As an activity standard, the human bFGF international standard (WHO International Standard FGF-2, Human, rDNA derived, NIBSC code: 90 / 712, Specific Activity; 8.0 × 10 5 U / mg). The bbFGF concentration in the crude purified fraction B was determined by reverse phase HPLC using bFGF (basic FGF) Solution, Human, Recombinant (154 aa), Animal-Free (Cat#19155-07 manufactured by NACALAITESQUE) as a standard. As a result, the cell proliferation activity value (Specific Activity) of the crude purified fraction B was 2.5×10 6 U / mg.

[0377] (Example 4) Evaluation of the biological activity of bovine basic fibroblast growth factor (bbFGF) secreted by Corynebacterium glutamicum-3

[0378] (4-1) Preparation of crude purified bbFGF fraction C

[0379] Corynebacterium glutamicum YDK0107Δpmt1 / pPK10_TorAss-bbFGF strain was cultured in a fermentation tank according to a known method (Hiroshi Itaya and Yoshimi Kikuchi. Secretion of Streptomyces mobaraensis pro-transglutaminase by coryneform bacteria. ApplMicrobiol Biotechnol. 2008; 78(4): 621-625.). Dithiothreitol was added to the centrifugal supernatant of the culture solution in a manner of 1.03 mg / mL. After standing for 15 minutes, an ultrafiltration membrane with a molecular weight of 3000 was used and the solvent was replaced with a solution in which dithiothreitol was added to PBS (Cat#: 14190 manufactured by THERMO FISHER SCIENTIFIC). Sterile filtration was performed using a 0.22 μm PVDF membrane filter. This was designated as crude purified fraction C and stored frozen at -80°C until the biological activity was evaluated.

[0380] (4-2) Activity Assay of bbFGF Crude Purification Fraction C

[0381] The activity of the crude purified fraction C obtained above was measured by cell proliferation activity using BALB / c 3T3 cells. As an activity standard, human bFGF international standard (WHO International Standard FGF-2, Human, rDNA derived, NIBSC code: 90 / 712, Specific Activity; 8.0 × 10 5 U / mg). The bbFGF concentration in the crude purified fraction C was determined by reverse phase HPLC using bFGF (basic FGF) Solution, Human, Recombinant (154 aa), Animal-Free (Cat#19155-07 manufactured by NACALAITESQUE) as a standard. As a result, the cell proliferation activity value (Specific Activity) of the crude purified fraction C was 3.1×10 6 U / mg.

[0382] (Example 5) Evaluation of the biological activity of bovine basic fibroblast growth factor (bbFGF) secreted by Corynebacterium glutamicum

[0383] (5-1) Preparation of crude purified fraction D of bbFGF

[0384] Corynebacterium glutamicum YDK0107Δpmt1 / pPK10_TorAss-bbFGF strain was cultured in a fermentation tank according to a known method (Hiroshi Itaya and Yoshimi Kikuchi. Secretion of Streptomyces mobaraensis pro-transglutaminase by coryneform bacteria. ApplMicrobiol Biotechnol. 2008; 78(4): 621-625.). The supernatant of the culture solution was adjusted to pH 6.5 using 50% acetic acid, and then dithiothreitol (DTT) was added to 27 mg / mL and dissolved. After standing for 15 minutes, water was added to a conductivity of 9.5 mS / cm (25°C). The solution was filtered using a 0.22 μm PVDF membrane filter and used as a loading solution for cation exchange chromatography. As for the column, HiTrap SP FF (Cat#: 17504501 manufactured by Cytiva) was used, and after equilibration with A-buffer (a solution prepared by adding 908 mL of water to 5.7 g of disodium hydrogen phosphate, 11.7 g of sodium dihydrogen phosphate, 0.15 g of DTT, and 5.4 g of sodium chloride), the loading solution was loaded. After re-equilibration with A-buffer, elution was performed with a gradient (0-100%: 20CV) in B-buffer (a solution prepared by adding 1000 mL of water to 3.6 g of disodium hydrogen phosphate, 0.15 g of DTT, and 6.0 g of sodium chloride and adjusting the pH to 8.0, and then adding sodium chloride to the obtained solution in a manner to make it 1 M) ( Figure 2 The peak fractions were collected as crude purified fraction D and stored frozen at -80°C until the biological activity was evaluated.

[0385] (5-2) Activity determination of crude purified fraction D of bbFGF

[0386] The activity of the crude purified fraction D obtained above was measured by cell proliferation activity using BALB / c 3T3 cells. As an activity standard, human bFGF international standard (WHO International Standard FGF-2, Human, rDNA derived, NIBSC code: 90 / 712, Specific Activity; 8.0 × 10 5U / mg). The bbFGF concentration in the crude purified fraction D was determined by reverse phase HPLC using bFGF (basic FGF) Solution, Human, Recombinant (154 aa), Animal-Free (Cat#19155-07 manufactured by NACALAITESQUE) as a standard. As a result, the cell proliferation activity value (Specific Activity) of the crude purified fraction D was 2.3×10 6 U / mg.

[0387] (Example 6) Evaluation of the biological activity of bovine basic fibroblast growth factor (bbFGF) secreted by Corynebacterium glutamicum

[0388] (6-1) Preparation of crude purified fraction E of bbFGF

[0389] Corynebacterium glutamicum YDK0107Δpmt1 / pPK10_TorAss-bbFGF strain was cultured in a fermentation tank according to a known method (Hiroshi Itaya and Yoshimi Kikuchi. Secretion of Streptomyces mobaraensis pro-transglutaminase by coryneform bacteria. ApplMicrobiol Biotechnol. 2008; 78(4): 621-625.). The supernatant of the culture solution was adjusted to pH 6.5 using 50% acetic acid, and then dithiothreitol was added to 27 mg / mL and dissolved. After standing for 15 minutes, water was added to a conductivity of 9.5 mS / cm (25°C). The solution was filtered using a 0.22 μm PVDF membrane filter and used as a loading solution for cation exchange chromatography. As for the column, HiTrap SP FF (Cat#: 17504501 manufactured by Cytiva) was used, and after equilibration with A-buffer (a solution prepared by adding 908 mL of water to 5.7 g of disodium hydrogen phosphate, 11.7 g of sodium dihydrogen phosphate, 1.7 g of EDTA, and 5.4 g of sodium chloride), the loading solution was loaded. After re-equilibration with A-buffer, elution was performed with a gradient (0-100%: 20CV) of B-buffer (a solution prepared by adding 1000 mL of water to 3.6 g of disodium hydrogen phosphate, 1.9 g of EDTA, and 6.0 g of sodium chloride to obtain a 1M solution) ( Figure 3 ). Collect the peak fractions ( Figure 3 , collected (pool), using an ultrafiltration membrane with a molecular weight of 3000, the solvent was replaced with a solution obtained by adding dithiothreitol to PBS (Cat#: 14190 manufactured by THERMO FISHER SCIENTIFIC) in a manner of 154 mg / L. Sterile filtration was performed using a 0.22 μm PVDF membrane filter. This was used as a crude purified fraction E and was frozen and stored at -80°C until the biological activity was evaluated.

[0390] (6-2) Activity Assay of bbFGF Crude Purification Fraction E

[0391] The activity of the crude purified fraction E obtained above was measured by cell proliferation activity using BALB / c 3T3 cells. As an activity standard, the human bFGF international standard (WHO International Standard FGF-2, Human, rDNA derived, NIBSC code: 90 / 712, Specific Activity; 8.0 × 10 5 U / mg). The bbFGF concentration in the crude purified fraction E was determined by reverse phase HPLC using bFGF (basic FGF) Solution, Human, Recombinant (154 aa), Animal-Free (Cat#19155-07 manufactured by NACALAITESQUE) as a standard. As a result, the cell proliferation activity value (Specific Activity) of the crude purified fraction E was 2.6×10 6 U / mg.

[0392] As shown in Examples 2 to 6, all fractions showed high cell proliferation activity values. That is, bbFGF produced by using coryneform bacteria as expression hosts was found to be suitable for animal cell culture (specifically, production of cultured meat). In particular, bbFGF produced by using coryneform bacteria as expression hosts was found to be suitable for animal cell culture (specifically, production of cultured meat) even without purification to high purity by chromatography or the like.

[0393] (Example 7) Evaluation of the biological activity of bovine basic fibroblast growth factor (bbFGF) secreted by Corynebacterium glutamicum

[0394] (7-1) Preparation of bovine muscle stem cells

[0395] Muscle tissue was collected from edible beef shanks, and magnetic cell sorting (MACS) was used to separate CD56-positive cells as bovine muscle stem cells.

[0396] (7-2) Evaluation of bbFGF activity using bovine muscle stem cells in serum-free medium

[0397] The bovine muscle stem cells obtained above were suspended in a serum medium. As the serum medium, Advanced DMEM (Thermo Fisher Scientific, Cat No. 12491015) supplemented with 20% FBS (Thermo Fisher Scientific, Cat No. 10270106), 10% horse serum (ThermoFisher Scientific, Cat No. 16050-130) and 1% GlutaMAX was used. TM Supplement (Thermo Fisher Scientific, Cat No. 35050061). The cells were suspended at a concentration of 5300 cells / 2 mL / cm 2 The cells were inoculated at a density of 1 μg / cm 2 6-well plates (Cat#353046, BD FALCON) coated with fibronectin (Cat#F2006, Corning) were used, and the medium was replaced every other day. On the fourth day after the start of culture, the cells were passaged to serum-free medium without bbFGF or serum-free medium containing bbFGF, and the medium was replaced every other day. As serum-free medium without bbFGF, StemFit RBasic03 (manufactured by Ajinomoto) was supplemented with 5 ng / mL HGF (Cat#294HGN005 manufactured by Peprotech) and 0.5 mg / mL soy protein acid hydrolysate (Soy protein acid hydrolysate) (Cat#S1674 manufactured by Sigma). As a serum-free medium containing bbFGF, a medium in which bbFGF crude purification component A, bbFGF crude purification component E or animal-free recombinant bovine FGF-basic (Animal-Free Recombinant Bovine FGF-basic) (Cat#AF-450-62 manufactured by Peprotech) was added at 0.1, 1 or 10 ng / mL to a serum-free medium without bbFGF was used. The group numbers and culture media are summarized in Table 1. Cell counting and passage were performed every 4 days, and the proliferation rate and doubling time of 2 consecutive passages from the 4th day to the 12th day were calculated.

[0398] [Table 1]

[0399]

[0400] The results are as follows Figures 4 to 6 As shown. bbFGF crude purification fraction A, bbFGF crude purification fraction E and animal-free recombinant bovine FGF-basic can all promote the proliferation of bovine muscle stem cells in serum-free medium. That is, with respect to bbFGF produced using rod-shaped bacteria as expression hosts, it has been confirmed that it can be suitably used for the culture of animal cells (specifically, the production of cultured meat). In particular, with respect to bbFGF produced using rod-shaped bacteria as expression hosts, it has been confirmed that it can be suitably used for the culture of animal cells (specifically, the production of cultured meat) even without purification to a high purity by chromatography or the like.

[0401] (Example 8) Evaluation of the biological activity of bovine basic fibroblast growth factor (bbFGF) secreted by Corynebacterium glutamicum

[0402] (8-1) Preparation of bovine muscle stem cells

[0403] Muscle tissue was collected from edible beef shanks, and magnetic cell sorting (MACS) was used to separate CD56-positive cells as bovine muscle stem cells.

[0404] (8-2) Evaluation of bbFGF activity using bovine muscle stem cells

[0405] The bovine muscle stem cells obtained above were suspended in a serum medium. As the serum medium, Advanced DMEM (Thermo Fisher Scientific, Cat No. 12491015) supplemented with 20% FBS (Thermo Fisher Scientific, Cat No. 10270106), 10% horse serum (ThermoFisher Scientific, Cat No. 16050-130) and 1% GlutaMAX was used. TM Supplement (Thermo Fisher Scientific, Cat No. 35050061). The cells were suspended at a concentration of 5300 cells / 2 mL / cm 2 The cells were inoculated at a density of 1 μg / cm 2 6-well plates (Cat#353046, BD FALCON) coated with fibronectin (Cat#F2006, Corning) were used, and the medium was replaced every other day. On the fourth day after the start of culture, the cells were suspended in a serum-free medium without bbFGF or a serum-free medium containing bbFGF and passaged, and the medium was replaced every other day. As a serum-free medium without bbFGF, StemFit R Basic03 (manufactured by Ajinomoto) was supplemented with 5 ng / mL HGF (Cat#294HGN005 manufactured by Peprotech) and 0.5 mg / mL soy protein acid hydrolysate (Soy protein acid hydrolysate) (Cat#S1674 manufactured by Sigma). As a serum-free medium containing bbFGF, a medium in which bbFGF crude purification component B, bbFGF crude purification component C, bbFGF crude purification component D or animal-free recombinant bovine FGF-basic (Cat#AF-450-62 manufactured by Peprotech) was added at 0.1, 1 or 10 ng / mL to a serum-free medium without bbFGF was used. The group numbers and culture media are summarized in Table 2. The cell suspension was cultured at 5300 cells / 2 mL / cm 2 The cells were inoculated at a density of 1 μg / cm 2The medium was replaced every other day in a 6-well plate (Cat#353046, BD FALCON) coated with fibronectin (Cat#F2006, Corning). Cells were counted and passaged every 4 days, and the proliferation rate and doubling time of two consecutive passages from the 4th day to the 12th day were calculated.

[0406] [Table 2]

[0407]

[0408] The results are as follows Figures 7-9 As shown. bbFGF crude purification component B, bbFGF crude purification component C, bbFGF crude purification component D and animal-free recombinant bovine FGF-basic all promoted the proliferation of bovine muscle stem cells in serum-free medium. That is, with respect to bbFGF produced using rod-shaped bacteria as expression hosts, it has been confirmed that it can be suitably used for the cultivation of animal cells (specifically, the production of cultured meat). In particular, with respect to bbFGF produced using rod-shaped bacteria as expression hosts, it has been confirmed that it can be suitably used for the cultivation of animal cells (specifically, the production of cultured meat) even without purification to a high purity by chromatography or the like.

[0409] Industrial Applicability

[0410] The present invention enables efficient production of cultured meat.

[0411] [Explanation of Sequence Listing]

[0412] SEQ ID NO.1: Base sequence of the phoS gene of Corynebacterium glutamicum YDK010

[0413] SEQ ID NO.2: Amino acid sequence of PhoS protein of Corynebacterium glutamicum YDK010

[0414] SEQ ID NO.3: Amino acid sequence of PhoS protein of Corynebacterium glutamicum ATCC 13032

[0415] SEQ ID NO.4: Amino acid sequence of PhoS protein of Corynebacterium glutamicum ATCC 14067

[0416] SEQ ID NO.5: Amino acid sequence of PhoS protein from C. callunae

[0417] SEQ ID NO.6: Amino acid sequence of PhoS protein of C. crenatum

[0418] SEQ ID NO.7: Amino acid sequence of PhoS protein of C. efficiens

[0419] SEQ ID NO.8: Base sequence of phoR gene of Corynebacterium glutamicum ATCC 13032

[0420] SEQ ID NO.9: Amino acid sequence of PhoR protein of Corynebacterium glutamicum ATCC 13032

[0421] SEQ ID NO.10: Base sequence of cspB gene of Corynebacterium glutamicum ATCC 13869

[0422] SEQ ID NO.11: Amino acid sequence of CspB protein of Corynebacterium glutamicum ATCC 13869

[0423] SEQ ID NO.12: Base sequence of tatA gene of Corynebacterium glutamicum ATCC 13032

[0424] SEQ ID NO.13: Amino acid sequence of TatA protein of Corynebacterium glutamicum ATCC 13032

[0425] SEQ ID NO.14: Base sequence of tatB gene of Corynebacterium glutamicum ATCC 13032

[0426] SEQ ID NO.15: Amino acid sequence of TatB protein of Corynebacterium glutamicum ATCC 13032

[0427] SEQ ID NO.16: Base sequence of tatC gene of Corynebacterium glutamicum ATCC 13032

[0428] SEQ ID NO.17: Amino acid sequence of TatC protein of Corynebacterium glutamicum ATCC 13032

[0429] SEQ ID NO.18: Amino acid sequence of TorA signal peptide

[0430] SEQ ID NO.19: Amino acid sequence of SufI signal peptide

[0431] SEQ ID NO.20: Amino acid sequence of PhoD signal peptide

[0432] SEQ ID NO.21: Amino acid sequence of LipA signal peptide

[0433] SEQ ID NO.22: Amino acid sequence of IMD signal peptide

[0434] SEQ ID NO.23: Amino acid sequence of twin arginine motif

[0435] SEQ ID NO.24: skipped sequence

[0436] SEQ ID NO.25: Amino acid sequence of PS1 signal peptide

[0437] SEQ ID NO.26: Amino acid sequence of PS2 signal peptide

[0438] SEQ ID NO.27: Amino acid sequence of SlpA signal peptide

[0439] SEQ ID NO.28: Amino acid sequence of CspB mature protein of Corynebacterium glutamicum ATCC 13869

[0440] SEQ ID NO.29~31: skipped sequence

[0441] SEQ ID NO.32-36: Amino acid sequence of one embodiment of the insertion sequence used in the present invention

[0442] SEQ ID NO.37: Recognition sequence of Factor Xa protease

[0443] SEQ ID NO.38: Recognition sequence of ProTEV protease

[0444] SEQ ID NO.39: Base sequence of the PMT gene of Corynebacterium glutamicum ATCC 13869

[0445] SEQ ID NO.40: Amino acid sequence of PMT of Corynebacterium glutamicum ATCC 13869

[0446] SEQ ID NO.41~44: Primer

[0447] SEQ ID NO.45: Base sequence of bbFGF gene

[0448] SEQ ID NO.46: Amino acid sequence of bbFGF

[0449] SEQ ID NO.47: Base sequence of TorAss-bbFGF

[0450] SEQ ID NO.48: Amino acid sequence of TorAss-bbFGF

Claims

1. A method for producing bovine basic fibroblast growth factor (bbFGF) for use in the production of cultured meat, comprising: A step of culturing coryneform bacteria having a gene construct for secretory expression of bbFGF to obtain a culture containing bbFGF.

2. The method according to claim 1, further comprising: A step of removing the bacterial cells of the coryneform bacteria from the culture.

3. The method according to claim 1 or 2, which does not comprise: Procedure for purifying bbFGF.

4. The method according to any one of claims 1 to 3, which does not comprise: A step of purifying bbFGF by chromatography.

5. The method according to any one of claims 1 to 4, wherein The gene construct comprises, from 5' to 3' direction, a promoter sequence that functions in coryneform bacteria, a nucleic acid sequence encoding a signal peptide that functions in coryneform bacteria, and a nucleic acid sequence encoding bbFGF, bbFGF was expressed as a fusion protein with the signal peptide.

6. The method according to any one of claims 1 to 5, wherein The coryneform bacteria are bacteria of the genus Corynebacterium.

7. The method according to any one of claims 1 to 6, wherein The coryneform bacteria is Corynebacterium glutamicum.

8. A method for producing cultured meat, comprising: The process of culturing animal cells in the presence of bovine basic fibroblast growth factor (bbFGF), In the method for producing cultured meat, bbFGF is produced by the method according to any one of claims 1 to 7.